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Abstract 
His-Asp signaling systems are ubiquitous in bacteria, archaea, and certain plants and 
fungi.  Little structural information is known about the protein-protein interactions 
within these signaling pathways, leaving an incomplete picture of how these essential 
systems operate.  In this dissertation, the focus of my work in the West laboratory was 
the receiver domain of the fungal response regulator protein Ssk1, and its interaction 
with the histidine phosphotransfer protein Ypd1.  In Saccharomyces cerevisiae (Sc), 
Ypd1 interacts with receiver domains from upstream Sln1 and downstream Ssk1 on a 
common hydrophobic docking site.  The main portion of this thesis presents the co-
crystal complex of Ypd1 and Ssk1-R2W638A and the accompanying analysis to explain 
key differences in the physiological functions of Ssk1-R2 and Sln1-R1.    Protein-
protein interactions were characterized using a newly developed fluorescence binding 
assay and in vitro 32P-phosphotransfer experiments.  In addition, the co-crystallization 
of Ssk1-R2W638A and a point mutant of Ypd1 (Ypd1-G68Q) is described.  Ssk1 protein 
constructs from the human pathogen Cryptococcus neoformans (Cn) were designed in 
order to biochemically characterize interactions with C. neoformans Ypd1, but these 
proteins were either insoluble or inactive.    Lastly, my work in the Cichewicz 
laboratory describes the discovery of three new secondary metabolites from a 
previously uncharacterized microbial mat fungus (clearanols C, D and E). 
  
1 
Chapter 1: Introduction 
Two-component signal transduction 
Two-component signal transduction is a form of intracellular communication 
used by bacteria, archaea, and certain plants and fungi.  Basic two-component systems 
are comprised of two signaling proteins: an upstream sensor histidine kinase (HK) that 
responds to an extracellular signal by binding ATP and autophosphorylating a histidine 
residue, and a downstream response regulator (RR) protein that controls the output 
response of an attached effector domain.  RR proteins contain receiver (rec) domains 
that have conserved aspartate residues as phosphoryl group acceptors from the histidine 
of the HK.  The RR is responsible for transmitting a signal to a downstream effector to 
elicit an appropriate cellular response (Figure 1, panel A (pg. 2)) (reviewed in1, 2). 
Basic two-component signaling (TCS) systems are found in bacteria, and they 
are the primary strategy by which these organisms interact with and respond to their 
environments. Bacteria use TCS systems for stress response, cell growth and 
propagation, as well as cell cycle transitions (reviewed in1, 3-5 6).   Most bacteria contain 
as many as 20-30 HK-RR pairs, with some possessing hundreds, each responding to 
different environmental signals, stressors and changes7-10.  For example, the 
CheY/CheA chemotaxis system in Escherichia coli is one of the most highly studied 
two component systems in the field11.  Other well-characterized systems include the 
oxygen-sensing nitrogen-fixation FixJ/FixL system of Sinorhizobium meliloti12, the 
osmosensing EnvZ/OmpR system of E. coli13, 14, and the intracellular Mg2+ detection 
system PhoQ/PhoP (reviewed in15). 
2 
The molecular mechanisms for regulating these large pools of signaling proteins 
and preventing cross-talk between pathways are not fully understood.  Current studies 
suggest that organisms use a combination of molecular recognition as well as co-
localization and concentration-based methods in order to ensure molecular specificity 
and prevent heterologous cross-talk8, 16-19.  These same mechanisms would be necessary 
to maintain the integrity of a single pathway, especially if such a system was expanded 
to have multiple points of regulation. 
 
Figure 1.  Illustration of TCS vs. multi-step phosphorelay.   
Panel A shows a two-component system (HK + RR).  Panel B shows an expanded phosphorelay system 
(hybrid HK + HPt + RR).  Non-phospho-accepting domains are not shown for simplicity. 
 
Multi-step phosphorelay systems 
A multi-step phosphorelay system is an expanded version of the simple two 
component system (reviewed in1, 20-22). These signaling pathways also use histidine to 
aspartate phosphotransfer to transmit messages and respond to the external 
environment.  These pathways begin with a hybrid sensor HK, which is similar in 
structure and function to a basic HK, but contains an attached receiver domain in 
addition to its HK domain, usually at the C-terminus.  The HK responds to an external 
3 
stimulus, autophosphorylates on a histidine residue using the γ-phosphate from ATP, 
and then passes the phosphoryl group intramolecularly to an aspartate residue located in 
its receiver domain.  The receiver domain then interacts with a histidine 
phosphotransfer protein (HPt), which acts as an intermediate in the signaling pathway.  
The HPt receives the phosphoryl on a histidine residue and then interacts with the 
receiver domain located on a downstream RR protein.  The RR protein completes the 
signaling response, either through direct alterations in cellular behavior, or through 
further activation of downstream pathways (Figure 1, panel B (pg. 2)) (reviewed in1).  
Multi-step phosphorelay pathways and HPt domains are most commonly found in 
certain eukaryotic organisms like plants and fungi, but they can also be found in 
bacteria, such as the E. coli proteins ArcB and BarA9, 23.  It has been suggested that 
hybrid histidine kinases make up approximately 30% of all known bacterial kinase 
proteins, though not all are necessarily involved in expanded phosphorelays22, 24. 
Use of a multi-step phosphorelay provides an organism with several possible 
advantages when compared to simple TCS systems.  The increased number of signaling 
components provides additional points of regulation for the cell25.  Mathematical 
modeling of phosphorelays suggests that the increased length of a phosphorelay can 
result in a more ultrasensitive character26, 27.  This ultra-sensitivity imparts a switch-like 
quality to the intermediate components, leading to very low responses for inputs below 
a determined threshold, and very high and rapid responses once the threshold has been 
reached26.  This results in a sigmoidal signal-response curve that can be fine-tuned as 
needed by the organism.  The presence of a signal threshold will also reduce pathway 
activation through promiscuous cross-talk and filter out input noise26-28. 
4 
Histidine kinase proteins 
 In TCS pathways, HK proteins are responsible for sensing, internalizing and 
propagating external stimuli to the cellular machinery required for an appropriate 
cellular response. There are different classes of HKs: proteins with extracellular, 
transmembrane or intracellular sensor domains (reviewed in1, 21, 29).  In general, the 
canonical HK is a multi-domain homodimer with an extracellular sensor domain.  The 
architecture of an HK monomer begins with an N-terminal transmembrane helix that 
leads to the extracellular sensory domain (reviewed in30).  The extracellular sensory 
domain is linked to another antiparallel transmembrane helix which bundles with the 
first helix.  This is followed by a variable cytoplasmic signal transducing domain (e.g. 
PAS, HAMP or GAF domain), followed by the dimerization and histidine 
phosphotransfer (DHp) domain which is composed of two antiparallel helices.  A 
flexible loop connects the DHp and ATP-binding catalytic domain at the C-terminus.  
Two monomers form a homodimer resulting in the DHp domains forming a highly 
conserved 4-helix bundle.  Once the signal is transduced through the protein assembly, 
the HK switches from an inactive to an active state31, and the autophosphorylation 
reaction begins on the catalytic domain.  A conserved histidine residue is 
phosphorylated on helix 1 of the DHp domain.  After the histidine is phosphorylated, 
the phosphoryl is passed to an aspartate residue of a receiver domain.  If the protein has 
phosphatase activity, the DHp domain is also the site of this reaction (reviewed in30).   
On a homodimeric HK, the autophosphorylation mechanism was thought to 
occur only in trans with regard to the dimeric subunits32-36.  Recent studies suggest that 
this is not the case, with Staphylococcus aureus PhoR37 and E. coli ArcB38 behaving in 
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a cis manner exclusively.  Recent studies have shown that either mechanism is possible, 
and that the handedness of the hairpin loop connecting the two DHp helices determines 
which method is used39, 40.  If the loop turns right, the autophosphorylation proceeds in 
trans with the catalytic domain in closer proximity to its partner’s phosphorylatable 
histidine.  If the loop turns left, the autophosphorylation reaction occurs in cis with the 
catalytic domain in closer proximity to its own phosphorylatable histidine41.  As an 
example, an engineered catalytic domain bound with ATP is poised to 
autophosphorylate the histidine residue in cis (Figure 2), adapted from Casino et al.39 
 
Figure 2.  Catalytic and DHp domains of dimeric histidine kinase EnvZchim. 
Bound ATP is poised to autophosphorylate in cis (PDB ID: 4KP4).  Monomer A (green) is shown with 
bound Mg2+ (magenta) and ATP in position to phosphorylate the active site histidine residue (red).  
Monomer B (cyan) does not contain bound ATP. 
 
HK sensor domains are typically extracellular, asymmetrical and have many 
different modes of ligand binding, both in location and in method of binding2, 29, 42, 43.  
Additional classes of sensor domains do exist, such as transmembrane and intracellular 
6 
receptors.  Some examples of HK ligands are aspartate, triethylamine N-oxide, nitrate, 
magnesium, citrate, malonate and other ligand-bound proteins44-47.  Regardless of how 
the signal is received, ligand-binding causes a structural rearrangement from an inactive 
conformation to an active conformation, initiating autophosphorylation by the kinase 
domain (reviewed in30).   
The catalytic domain is a highly conserved α/β sandwich composed of three α-
helices packed against five antiparallel β-strands.  ATP binds between two helices and 
is held in place by a loop called the “ATP lid.”  ATP associates with conserved 
sequence motifs called N, G1, G2 and F that comprise the nucleotide binding sites48.  A 
hydrophobic “gripper” helix associates with the DHp domain in different orientations 
during the transition from the inactive to active conformation (reviewed in30).  Once the 
active conformation is achieved, the CA and DHp domain are interfacing through 
specific residue contacts.  A string of seven highly conserved residues on helix 1 of the 
DHp domain (H box) participates in catalysis (Table 1).  Residues 5-6 participate in 
helix bending; basic residue 4 stabilizes the negatively charged phosphate groups on 
ATP, acidic residue 2 acts as a hydrogen bond acceptor or general acid/base while 
histidine 1 is phosphorylated using the γ-phosphate of ATP to form a high energy Nε-P 
bond30.  
 
Table 1.  DHp domain H-box residues 
1 2 3 4 5 6 7 
H D/E L/I K/R T/N P L 
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Histidine phosphotransfer proteins 
Histidine phosphotransfer proteins are proteins that appear in multi-step 
phosphorelays (reviewed in49).  Their function is to accept a phosphoryl group from an 
aspartate on an upstream receiver domain of a hybrid histidine kinase and shuttle it to 
an aspartate on a downstream RR (reviewed in1).  HPt proteins contain a conserved 4-
helix bundle core, reminiscent of the HK 4-helix bundle.  The structure of Ypd1, an HPt 
protein from S. cerevisiae, was solved in 199950, 51 (Figure 3 (pg. 8)), revealing the 
conservation of structure and function of HPt domains.  There are several highly 
conserved residues that contribute to HPt protein activity.  A residue four positions 
away (n+4) from the phosphorylatable histidine is a highly conserved glycine that 
potentially allows access to the histidine during phosphotransfer.  A structurally 
significant glycine located between the C and D helices is also highly conserved, and is 
likely essential to the hydrophobic reverse turn between the C and D helices.  Two 
conserved basic residues are proposed to participate in the proper antiparallel 
orientation of the C and D helices.  In addition, a polar residue (glutamine or glutamate) 
hydrogen bonds with the phosphorylatable histidine and with the assistance of a water 
molecule, positions the histidine in the proper orientation for phosphotransfer52. 
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Figure 3.  Ribbon representation of S. cerevisiae HPt protein Ypd1.  
The Ypd1 structure was solved in 199950 (PDB ID: 1QSP).  Alpha helices (A-G) are labeled and the 
phospho-accepting histidine residue (H64) is shown in stick.   
 
Response regulator proteins 
Response regulators are signaling proteins that control output responses in all 
TCS and phosphorelay pathways.  A defining feature of an RR is the presence of a 
receiver domain.  Receiver domains have highly conserved tertiary structures and 
contain a phosphorylatable active site aspartate residue (reviewed in1, 53).   Although 
structurally conserved, sequence identity is relatively low, ranging from 25-30% within 
the large superfamily of RR protein receiver domains (>300,000 in the National Center 
for Biotechnology Information (NCBI) database: 
http://pfam.xfam.org/family/response_reg, accessed 2015).  RR proteins can be either 
single or multi-domain proteins1, 54.  For example, CheY is a bacterial chemotaxis RR 
that is comprised of only a single receiver domain55.  Bacterial RR proteins typically 
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contain an N-terminal receiver domain and a C-terminal effector domain.  In 
eukaryotes, many receiver domains are found at the C-terminal end of the RR protein.  
The purpose of all receiver domains is to accept a phosphoryl group from a phospho-
histidine.  Aspartate phosphorylation stabilizes a universally conserved allosteric 
rearrangement of the receiver domain along the β4α4 and β5α5 surface of the protein 
(Figure 4 (pg. 10)).  Post-activation protein function can vary widely between signaling 
pathways.   
Functions of RR proteins are extremely diverse and depend greatly on the 
identity of the effector domain.  In addition to being involved in many different types of 
signaling pathways (oxidative stress response56, hyperosmotic stress response57, cell 
wall stress58, chemotaxis59, biofilm formation60, etc.), they perform many different 
functions on various cellular levels.  Depending on the effector domain, an RR protein 
can affect the cell at the transcriptional, post-transcriptional or post-translational level.  
The majority of effector domains function as transcription factors, grouped into three 
major subfamilies based on the homology of their DNA-binding domains1, 53, 61.  Other 
known effector domain functions include RNA-binding, ligand-binding, protein-
binding, and enzymatic activity (reviewed in53).  In addition to this diversity, the 
functions of many effector domains remain unknown62. 
Receiver domains almost invariably adopt a (βα)5 topology (reviewed in53).   
Alternating beta strands and alpha helices form a parallel beta-sheet flanked on both 
sides by 5 amphipathic alpha helices (Figure 4 (pg. 10)).  Conserved residues that 
contribute to phosphotransfer are primarily located at the C-terminal ends of the beta 
strands.  The phosphorylatable aspartate residue is located at the end of the β3 strand 
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and is one of three conserved acidic residues that participate in binding a divalent metal 
cation essential for phosphotransfer activity63. The other two acidic residues are located 
at the tip of the β1 strand.  Other active site residues include a lysine (β5)64 and a 
conserved “switch” residue, a threonine/serine (β4)65, that participate in the phospho-
induced conformational change.  A structurally essential proline is located on the loop 
between β3 and α3 followed by a glycine four residues away.  A moderately conserved 
aromatic residue (Phe/Tyr) on the α5 helix is also referred to as a “switch residue” along 
with the conserved threonine/serine that interacts with the phosphoryl group.  There is 
evidence that RRs sometimes act in concert with other proteins for activation66 and 
atypical RRs have been found that do not rely on phosphorylation for activation67. 
 
 
Figure 4.  Ribbon representation of RR protein CheY. 
Beta strands (1-5) and alpha helices (1-5) are labeled; the phospho-accepting aspartate residue (D57) and 
the Mg2+-coordinating aspartates (D12 and D13) are shown in stick.  Mg2+ is shown as a magenta sphere.  
The left panel shows the inactive structure of CheY from Salmonella enterica68 (PDB ID: 2CHE).  The 
right panel shows the BeF3--activated structure of CheY from E. coli69 (PDB ID: 1FQW).  This figure 
illustrates that upon activation, an allosteric movement occurs from α4 through α5. 
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 Although receiver domains accept phosphoryl groups from phospho-histidine, 
they play a catalytic role in phosphotransfer chemistry and are not passive “receivers.”  
Many receiver domains have the ability to autophosphorylate using small molecule 
phospho-donors70, 71.  The reaction is believed to involve a nucleophilic attack on the 
phosphate group by the aspartate carboxylate oxygen not bound to the divalent metal 
cation72.  Protein-protein phosphotransfer likely occurs in the same fashion.  Receiver 
domains also have autodephosphorylation activity that is believed to occur by the 
reverse mechanism, involving an activated water molecule executing an in-line 
nucleophilic attack on the phosphorus atom73 as the negatively charged oxygens are 
stabilized by the active site residues and metal ion1, 63. 
Phosphotransfer mechanism 
 The mechanism of His-Asp protein phosphotransfer in TCSs cannot be directly 
visualized because the static nature of crystal structures can only show the inactive and 
activate conformations.  However, research has been done on other signaling enzymes 
(reviewed in74) and a recent review of the current understanding of biological 
phosphoryl transfer mechanisms is an excellent resource that can add to our 
understanding of RR activity75.  Response regulators are believed to exist in an 
equilibrium of “inactive” and “active” conformations, and the active states are stabilized 
by phosphorylation76.   
 In general, a histidine or aspartate acts as a nucleophile and attacks the 
positively charged phosphorus of the phosphoryl group covalently bound to the donor 
atom.  A divalent metal cation in the active site of RRs is essential for this reaction to 
occur in either direction.  This metal is likely responsible for neutralizing charges on the 
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pentavalent transition state and it is hypothesized that this stabilization allows for the 
mechanism to occur77.  Factors that affect the character of a phosphotransfer mechanism 
are the strength of the attacking nucleophile and the stability of the leaving group.  In 
proteins, these variables are strongly influenced by amino acid side chain or backbone 
contributions that can donate or withdraw electrons from the donor or acceptor.   
Mechanisms for phosphoryl transfer are believed to occur with partial 
associative character78, including Sln1-R1 to Ypd179.  Known cell signaling enzymes 
range from ≤8% – 50% associative character74.  In the case of protein phosphotransfer, 
mechanisms are not described as associative or dissociative, but defined along a 
continuum, depending on the tightness of the hypothesized transition state (Figure 5).  
Assumptions about the mechanistic pathway have been inferred from co-crystal 
structures by measuring donor-acceptor atom distances and active site geometries39, 78. 
 
Figure 5.  Continuum of phosphoryl transfer transition states.   
Adapted from75. 
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S. cerevisiae Sln1 phosphorelay pathway 
The yeast S. cerevisiae has been used extensively as a model organism80.  This is 
because of its genetic tractability and the presence of only a single multi-step 
phosphorelay system.  Pathogenic fungi contain homologous pathways that are not 
found in mammals, making these systems valuable putative drug targets.  The highly 
nonspecific nature of current antifungal treatments has greatly increased the urgency to 
understand these signaling pathways81. 
The Sln1 pathway was first identified in the early 1990s82, 83 and has been 
studied extensively as an archetypal phosphorelay system.  The main function of the 
pathway in S. cerevisiae is to trigger downstream stress reactions such as the HOG1 
pathway in response to hyperosmotic stress or the Skn7 transcription factor to maintain 
cell wall integrity84 or respond to oxidative stress85.   
Sln1 is a homodimeric transmembrane hybrid histidine kinase that contains 1220 
residues86.  It is catalytically active under normal environmental conditions; it 
autophosphorylates on a histidine residue, passes this phosphoryl to an aspartate on its 
C-terminal receiver domain (R1) which passes the phosphoryl to Ypd1, the 167- residue 
intermediate HPt protein.  Ypd1 was identified as playing a role in the Sln1 pathway in 
199686 and it is dispersed throughout the cytoplasm and nucleus87.  Under normal 
conditions, Ypd1 constitutively phosphorylates Ssk1, a downstream response regulator, 
suppressing its ability to activate the HOG1 pathway86.  Under hyperosmotic stress, 
Sln1 responds to changes in turgor pressure and membrane fluidity (reviewed in88), and 
unphosphorylated Ssk1 accumulates in the cell and interacts with Ssk2 or Ssk22, 
MAPKKKs that initiate the HOG1 pathway glycerol production response86.  Under cell 
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wall or oxidative stress, Ypd1 phosphorylates the response regulator, Skn7, which is 
located in the nucleus.  Skn7 is a transcription factor and upregulates the appropriate 
genes in response to stress89, 90 (Figure 6). 
 
Figure 6. Illustration of the S. cerevisiae Sln1 pathway.   
Under normal conditions, Ypd1~P negatively regulates the HOG1 pathway via Ssk1.  Under 
hyperosmotic stress, dephosphorylated Ssk1 activates the HOG1 pathway. 
 
Differences between Ypd1 cognate receiver domains: Sln1-R1 and 
Ssk1-R2 
One of the main points of interest about the S. cerevisiae model Sln1 pathway is 
the ability of Ypd1 to interact with multiple receiver domains that are highly 
structurally similar yet result in distinctly different physiological outcomes.  Ypd1 
interacts with an upstream receiver domain (Sln1-R1) and two downstream receiver 
domains (Ssk1-R2 and Skn7-R3) on the same hydrophobic docking site91.  The forward 
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movement of the phosphorelay (Sln1-R1Ypd1Ssk1-R2) despite the similarity of 
Ypd1-interactions with its receiver domains, raises the fascinating question of how 
small changes in the receiver domains such as amino acid sequence or structural 
position can induce dissimilar biological behaviors. Following is a short review of the 
documented differences in biochemical behavior between Sln1-R1 and Ssk1-R2 in vitro 
and in vivo. 
In vitro rapid-quench phosphotransfer experiments show that the maximum rate 
of phosphotransfer from Sln1-R1 to Ypd1 is 29 ± 3 s-1,92.  The maximum rates of 
phosphotransfer from Ypd1 to each receiver domain are 230 ± 130 s-1 (Sln1-R1, reverse 
transfer) and 160 ± 70 s-1 (Ssk1-R2, forward transfer)92.  With respect to the 
phosphotransfer reaction, a phosphoryl group passing from phosphohistidine to a 
receiver domain aspartate is kinetically and energetically favored93, 94.  In the case of the 
Sln1 pathway, however, the phosphorelay must progress in the forward direction (Sln1-
R1  Ypd1  Ssk1-R2), so there must be important differences between the encounter 
complexes.  The rate of complex dissociation between Ypd1 and Sln1-R1 is 
approximately 30-fold faster than the rate of reverse phosphotransfer, allowing 97% of 
Ypd1 to remain phosphorylated and proceed in the forward direction.  When Ypd1 
encounters Ssk1-R2, the forward reaction is strongly favored and no reverse reaction 
from Ssk1-R2 to Ypd1 was detected under the conditions tested92.   
In addition to phosphotransfer kinetics, key residues on Ypd1 were found to 
play an important role in phosphotransfer from Sln1-R1 to Ypd1 but have no effect in 
the phosphorelay from Ypd1 to Ssk1-R2.  Ypd1 K67 and R90 were found to play an 
important role in positioning of the C and D helices and the electrostatic stabilization of 
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phosphorylated H6492.  From the Sln1-R1/Ypd1 crystal structures (Figure 7), Q86 
formed an intramolecular hydrogen bond to the imidazole ring of H64, likely orienting 
the residue for correct phosphoryl transfer from Sln1-R179, 95.  This evidence indicates 
that the electrostatic stabilization and orientation of Ypd1-H64 plays an essential role 
for the reception of a phosphoryl group from an upstream donor, but not necessarily for 
the forward phosphotransfer to Ssk1-R2. 
 
Figure 7.  Ribbon representations of the complexes between Ypd1 and Sln1-R1. 
The apo co-crystal structure of S. cerevisiae Sln1-R1/Ypd1 (A) was solved in 200396 (PDB ID: 1OXB) 
and the BeF3- -activated complex (B) was solved in 200879 (PDB ID: 2R25). 
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One residue was found to be essential for adequate phosphoryl transfer between 
Ypd1 and both cognate receiver domains: G68.  This glycine, located four residues 
from the phosphorylatable histidine, is almost completely conserved throughout HPt 
and HK domains (West lab, unpublished data).  In the case of Sln1-R1 to Ypd1 transfer, 
mutating G68 to glutamine decreased the rate of phosphotransfer by approximately 
9700-fold.  Between Ypd1 and Ssk1-R2, the decrease in phosphoryl transfer was 
approximately 670-fold92.  In conclusion, disruption of the Ypd1 n+4 glycine is 
approximately 15-fold more kinetically disruptive for accepting a phosphoryl from 
Sln1-R1 than transferring a phosphoryl to Ssk1-R2. 
In addition to structural and  in vitro data,  in vivo experiments indicate that 
unphosphorylated Ssk1 exists as a dimer in vivo, which activates Ssk2 resulting in 
HOG1 activation97.  The S. cerevisiae cell can turn off the HOG1 glycerol response by 
two known mechanisms:  phosphorylated Ssk1 can dimerize with unphosphorylated 
Ssk1 and inhibit its activity97; unphosphorylated Ssk1 is quickly degraded by the 
ubiquitin-proteasome system98. 
In vitro, receiver domains of Sln1 and Ssk1 show dramatically different 
phosphorylated lifetimes in the presence of Ypd1.  Ypd1 stabilizes the presence of 
Ssk1-R2~P and has no measureable effect on Sln1-R1~P99. This suggests the presence 
of a stable Ypd1/Ssk1-R2 complex99, 100.  These data support the physiological roles of 
Sln1-R1 and Ssk1-R2.  Sln1 must phosphorylate Ypd1 and quickly dissociate so that the 
phosphoryl can be passed to Ssk1.  Since phospho-Ssk1 is the inactive form of the 
protein, a stable complex between phospho-Ssk1 and Ypd1 would prevent the active 
unphosphorylated dimer of Ssk1 from accumulating and activating the HOG1 pathway. 
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Table 2.  Table of phosphorylated half-lives of Sln1-R1 and Ssk1-R2.   
Adapted from99 .  H64Q is an unphosphorylatable mutant. 
Receiver domain buffer +Ypd1 +Ypd1-H64Q 
Sln1-R1 t½ ~13 minutes t½ ~17 min t½ ~18 min 
Ssk1-R2 t½ ~13 minutes t½ ~ 40 hours t½ ~ 2.5 hours 
 
In an attempt to understand the mechanism of Ssk1-R2~P/Ypd1 dissociation, the 
half-life of Ssk1-R2~P was tested in the presence of osmolytes.  It was found that low 
concentrations of NaCl and glycerol decreased the half-life of Ssk1-R2~P in the 
presence of Ypd1 2-fold, but higher concentrations (up to 1 M) favored the stabilization 
of Ssk1-R2~P101.  These data corroborate the cell’s physiological response to 
hyperosmotic stress.  Initially, in the presence of high salt, water will be drawn out of 
the cell, temporarily increasing the intracellular osmolyte concentrations.  Under these 
circumstances, accumulation of unphosphorylated Ssk1-R2 would be favorable to turn 
on the HOG1 pathway.  Upon glycerol production and return to homeostasis, the 
stabilization of Ssk1-R2~P would be beneficial once again.   
Kinetic data support a significantly different interaction between Ypd1 and its 
cognate receiver domains (Sln1-R1 and Ssk1-R2), and there is strong data to support 
that Ypd1 and Ssk1-R2 form a stable phosphorylated complex99, 100 while Ypd1 and 
Sln1-R1 rapidly dissociate. However, yeast two-hybrid data show that the binding 
interface of Ypd1 is nearly identical for all of its cognate receiver domains.  Ypd1 
contains a hydrophobic patch surrounding the phosphorylatable histidine that acts as the 
binding interface for Sln1-R1, Ssk1-R2 and Skn7-R391, 102.  This indicates that there 
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must be minor but significant differences between the receiver domains and their 
interactions with Ypd1 that result in distinct physiological activities.   
Research Focus 
 Since the 1990’s, structural and biochemical data have been accumulating to 
shed light on the differences between Ypd1’s physiological interactions with Sln1-R1 
and Ssk1-R2.  To date, there has been no structural information about Ssk1 to help 
elucidate the mechanisms behind these key differences.  In this dissertation, I present 
the 2.80 Å co-crystal structure of a complex between S. cerevisiae Ypd1 and the 
receiver domain of Ssk1W638A.  The crystal structure illustrates differences from Sln1-
R1/Ypd1 in electrostatic interactions and active site encounter distances that may 
provide insight into the phosphorelay pathway regulation.  These data are supported by 
in vitro binding affinity and phosphotransfer assays that compare and contrast wild type 
(WT) protein interactions with Ssk1 point mutants.  Together, these data show 
structurally-based electrostatic potential interactions and key amino acids that are likely 
involved in the stable formation of an Ssk1~P/Ypd1 complex. The electrostatic 
contributions to complex formation can help explain the constitutive phosphorylation of 
Ssk1 in the Sln1 pathway of S. cerevisiae.   
 In order to elucidate more detailed information about the phosphorelay protein-
protein interactions of human pathogens, protein constructs of Cryptococcus 
neoformans Ssk1-R2 were designed.   These proteins were created to characterize 
binding interactions with C. neoformans Ypd1, but these constructs were either 
insoluble or inactive.   
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Chapter 2: Co-crystallization of an Ssk1-R2 point mutant (W638A) in 
complex with Ypd1 
Introduction 
 Structural information for Ypd1 and a complex with its upstream phospho-
donor, Sln1-R1, has significantly contributed to the knowledge of expanded 
phosphorelay systems and how they function in eukaryotic systems1-4.  Structural 
characterization of Ypd1 interfacing with its other cognate partners has been sought for 
many years.  This chapter details the methods that were used to obtain a co-crystal 
structure between Ypd1 and the receiver domain of its downstream cognate partner, 
Ssk1-R2W638A. 
Expression and purification of Ssk1-R2-W638A 
Before structural information was available, the functional significance of Ssk1 
amino acid residues was inferred using predicted structural homology models.  Non-
conservative mutations were introduced at sites in Ssk1-R2 that were predicted to 
interact with Ypd1 in order to gain insight into their biological functions.  The 
discovery of a beneficial point mutation in the receiver domain of Ssk1 led to notable 
purification improvements over the WT protein.  Mutating tryptophan 638 to alanine 
(W638A) resulted in a 15-fold increase in protein yield per gram of wet cell mass 
(Figure 8 (pg. 32)).  This point mutation also greatly increased the solubility of the Ssk1 
receiver domain.  In previous attempts, Ssk1-R2 could only be concentrated to ~2 
mg/mL before precipitating.  The W638A mutation allowed the protein to be 
concentrated up to >16 mg/mL, greatly increasing the likelihood of producing protein 
crystals. 
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Figure 8.  Ssk1-R2-WT vs. Ssk1-R2-W638A yield.   
15% Coomassie-stained SDS PAGE gel showing the increase in protein yield afforded by the W638A 
mutation from 2 L cultures.  Lane M: marker, lanes 2-4: 1 mL elutions from chitin columns of Ssk1-R2-
WT, lanes 6-9: 1 mL elutions from chitin columns of Ssk1-R2-W638A. 
 
Co-crystallization of Ypd1 in complex with Ssk1-R2-W638A 
The increase in yield and solubility of Ssk1-R2-W638A led to the successful co-
crystallization of Ypd1 and Ssk1-R2-W638A.  Ypd1 and Ssk1-R2-W638A were 
expressed and purified from E. coli, mixed in equimolar amounts and co-concentrated 
in 20 mM HEPES pH 7.0, 100 mM NaCl, 50 mM MgCl2 and 1 mM β-mercaptoethanol 
(βME).  The initial promising crystal lead came from well A5 of the MCSG-II 96-well 
screen at the University of Oklahoma Macromolecular Crystallography Laboratory 
(MCL). The proteins were set up in 24-well vapor diffusion hanging-drop trays around 
the neutral phosphate conditions of well A5 (MCSG-II).  The wells were clearly 
overnucleated and the crystals were very small (Figure 9 (pg. 33)).   
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Figure 9.  Initial co-crystals of Ypd1 and Ssk1-R2-W638A.   
The crystals were overnucleated and very small, indicating the need for optimization. 
 
Next, the proteins were mixed in equimolar amounts and co-concentrated in 50 
mM Tris pH 8.0, 100 mM NaCl and 1% glycerol.  This buffer change, determined by 
Dr. Smita Menon, resulted in crystals that reached 100-200 μm in diameter.  A single 
crystal was rinsed, dissolved in 1X Laemmli buffer and applied to sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to verify the presence of both 
proteins in the crystal (Figure 10).   
 
Figure 10.  Photograph of Ssk1-R2W638A/Ypd1 crystal. 
Photograph of Ssk1-R2W638A/Ypd1 crystal (left panel) and Coomassie-stained 15% SDS-PAGE gel of a 
dissolved crystal, verifying that the crystals were composed of both proteins (right panel, optimized 
crystal and gel courtesy of Dr. Smita Menon). 
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In order to obtain independent phasing information, a selenomethionine 
derivative of Ssk1-R2-W638A (Ssk1-R2W638ASeMet) was co-crystallized with Ypd1 
under similar conditions (Figure 11).  Data from these crystals were used to solve the 
final crystal structure. 
 
Figure 11.  Photograph of a Ypd1/Ssk1-R2W638ASeMet crystal.   
Photograph of Ssk1-R2W638ASeMet/Ypd1 crystal (left panel) and Coomassie-stained 15% SDS-PAGE gel of 
the co-concentrated proteins that were used to set up 24-well crystal trays (right panel). 
 
Co-crystal structure of Ssk1-R2W638A/Ypd1 
The Ssk1-R2 W638A/Ypd1 complex is the first structure of a eukaryotic HPt 
protein in complex with a downstream response regulator receiver domain (Figure 12 
(pg. 35)).  The crystal structure reveals that Ssk1-R2 adopts the canonical response 
regulator domain (βα)5 topology5.  The conserved site of phosphorylation on Ssk1 
(D554) is located on the C-terminal end of β3, positioned 6.3 Å away from H64, the site 
of phosphorylation on Ypd1.  This co-crystal structure represents the unphosphorylated 
“inactive” state.  The orientations of switch residues T610 from β4 and Y629 from β5 
are consistent with previously determined inactive structures; both are oriented “away” 
from the active site3, 6-9. 
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Figure 12.  Ribbon representation of the complex between Ypd1 and Ssk1-R2W638A. 
S. cerevisiae Ypd1 (green) has a four-helix bundle core; the active site histidine (H64) is shown in stick.  
The Ssk1W638A receiver domain (blue) adopts the canonical response regulator (βα)5 fold; the active site 
aspartate (D554) is shown in stick and the mutation site (W638A) is shown in cyan. 
 
Discussion 
Based on the co-crystal complex of Ssk1-R2W638A/Ypd1, point mutants on Ssk1-
R2 at the interface with Ypd1 were created and biochemically characterized with 
respect to binding affinity and phosphotransfer.  These data and a thorough comparison 
with the published structures of Ypd1 and Sln1-R14, 10 support a detailed biochemical 
explanation for the physiological function of Ssk1.  These topics will be discussed in 
extensive detail in Chapters 3 and 4. 
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Experimental Section 
Construction of mutants 
The Ssk1-R2-W638A mutant was created by QuikChange mutagenesis (see 
Appendix A) from the wild-type plasmid in the hybrid pET11a/pCYB2 vector. 
Protein Purification 
S. cerevisiae Ypd1 was purified from E. coli DH5α cells as a tag-less, full 
length, 167-residue protein1.  Ypd1 was constitutively expressed from a pUC19 plasmid 
(New England Biolabs (NEB)) for 19 hours at 37 °C, 200 rpm.  Cells were lysed by 
French Press in lysis buffer (100 mM sodium phosphate, pH 7.0, 1 mM EDTA, and 1 
mM βME) and the lysate was clarified by centrifugation for 1 hour at ~25,000 x g, 4 °C.  
Saturated ammonium sulfate was slowly added to the supernatant up to 55% by volume 
and stirred slowly at 4 °C for 30 minutes.  After centrifugation, the supernatant was 
discarded and the pellet was resuspended in dialysis buffer (20 mM BisTris pH 6.5, 1 
mM βME).  Dialysis into 2 L of buffer was performed twice to remove ammonium 
sulfate.  Protein was recovered and centrifuged to remove any debris and then filtered 
through a 0.45 µm syringe filter.   This sample was added to a 5 mL HiTrap Q anion 
exchange column (GE Healthcare) on an AKTA prime chromatography system and run 
in 20 mM BisTris pH 6.5 with increasing concentrations of NaCl (0-1 M).  Ypd1 
fractions were pooled, concentrated, filtered and added to a Sephadex® G-50 or 
Sephacryl® S-100 column in 20 mM Tris pH 8.0, 100 mM NaCl and 1% glycerol. 
Ssk1-R2-WT and Ssk1-R2-W638A were expressed in E. coli BL21 Star or Gold 
cells (Appendix B).  Two 1 L flasks of Luria Broth (LB) + ampicillin (100 µg/mL) were 
inoculated with 10 mL saturated cultures and grown at 37 °C, 200 rpm until OD600 > 
37 
0.8.  The temperature was changed to 16 °C and cultures were induced with 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and grown for approximately 22 hours.  
Cell pellets were kept for no longer than 24 hours at -20 °C before lysis.  Cells were 
lysed with French Press or an Emulsiflex (Avestin) and the lysate was clarified by 
centrifugation at ~25,000 x g for 1 hour at 4 °C.  Proteins were purified using chitin 
affinity chromatography (IMPACT system, NEB) as follows.  The cell lysate 
supernatant was added to a 3-4 mL chitin column pre-equilibrated in lysis buffer (20 
mM Tris pH 8.0, 500 mM NaCl, 1 mM EDTA, 10% glycerol and 0.1% Triton X-100).  
The flow-through (FT) was discarded and the column was washed with 10 column 
volumes (CV) of lysis buffer and 10 CV of cleavage buffer (20 mM Tris pH 8.0, 100 or 
500 mM NaCl, 10% glycerol).  The column was left to incubate overnight in cleavage 
buffer + 30 mM βME at 4 °C.   Cleaved protein was eluted with chelexed cleavage 
buffer (20 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol) and flash-frozen until ready 
for size-exclusion chromatography (Sephadex G®-75, Sephacryl® S-100 or S-200) in 
20 mM Tris pH 8, 100 mM NaCl and 1% glycerol.   
Crystallization and data collection 
Equimolar amounts of Ssk1-R2-W638A and Ypd1 were combined, co-
concentrated to 15 mg/mL and set up at room temperature in 96-well broad screens 
(Index, PACT, Wizard, CSHT, MCSG I-IV, and JCSG) in the MCL.  An initial 
promising lead came from well A5 of MCSG-II: 0.2 M lithium sulfate, 0.1 M 
CAPS/NaOH pH 10.5, 1.2 M NaH2PO4/0.8 M K2HPO4.  Fine 24-well vapor diffusion 
hanging drop screens were set up around these conditions.  Proteins were co-
concentrated in 20 mM HEPES pH 7.0, 100 mM NaCl, 50 mM MgCl2 and 1 mM βME.  
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The wells were clearly overnucleated and the crystals were very small.  To produce 
large, diffraction-quality crystals, the co-concentration buffer was changed to 50 mM 
Tris pH 8.0, 100 mM NaCl and 1% glycerol by Dr. Smita Menon.  These conditions 
produced crystals approximately 100-200 μm in diameter that diffracted to 3.0 Å at the 
MCL at the University of Oklahoma (Rigaku 007HF Micromax generator with Cu Kα 
line and a Dectris Pilatus 200K detector).  To collect independent phasing information, 
a heavy atom derivative was created.  Selenomethionine was introduced into the Ssk1-
R2-W638A protein and it was co-crystallized with Ypd1.  Crystals were grown in 24-
well vapor diffusion hanging-drop trays under the following conditions: 2-7 mg/mL 
concentrated protein in 20 mM Tris pH 8.0, 100 mM NaCl, and 1% glycerol (1:1 with 
well solution).  The best crystals were produced under the following well conditions:  
0.1 M CAPS pH 10.5, 1.0-1.2 M NaH2PO4, 0.1-0.2 M LiSO4, 0.8 M K2HPO4.  Dr. 
Smita Menon used 1.2 M NaH2PO4, 0.8 M K2HPO4, 0.2 M LiSO4, 0.1 M CAPS pH 
10.5, and 9% glycerol as the final cryo conditions for the co-crystals of Ypd1 and Ssk1-
R2W638A.  A multiple wavelength anomalous diffraction (MAD) data set was collected 
at the Stanford Synchrotron Radiation Lightsource (SSRL) on beam line 11-1. 
Structure determination and refinement 
The structure of the Ssk1-R2W638A response regulator receiver domain in 
complex with histidine phosphotransfer protein Ypd1 was solved by Dr. Smita Menon 
using phasing information obtained from MAD data and the program PHENIX-1.9-
169211.  After calculation of the initial electron density map, the initial crystallographic 
R-factor was 29.8% with an Rfree of 36.3%.  After several rounds of refinement using 
phenix.refine12, the R-factor dropped to 23.17% with an Rfree of 27.66%.  The final 
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model was refined to a resolution of 2.80 Å (Table 3).  Structure figures were generated 
using PyMOL13 or Chimera14. 
 
Table 3.  X-ray data collection and refinement statistics 
A. Data collection  Se-peak Se-remote Se-edge 
Wavelength (Å) 0.97910 0.9116 0.97930 
Temperature (K) 100 100 100 
Resolution (Å) 2.80 2.80 2.80 
Unique reflections 125302 124523 124773 
Redundancy 10.4 10.3 10.4 
Completeness (%) 99.8 (99.5) 99.8 (100.00) 99.8 (99.7) 
Mean I/σ (I) 43 (3.25) 40.6 (2.75) 42.7 (3.5) 
Rmerge (%) 0.065 (0.71) 0.062 (0.79) 0.065 (0.81) 
    
B. Crystal parameters    
Space group P43212 P43212 P43212 
Unit cell dimensions (Å) 71.69, 71.69, 
176.38 
71.73, 71.73, 
176.47 
71.74, 71.74, 
176.51  
Matthews’ coefficient (Å3/Da) 2.51   
Solvent content (%) 51.00   
    
C. Refinement    
Resolution range (Å) 33.27-2.80   
Number of protein atoms 2484   
Average B-factors (Å2) 42.19   
R-factor (%) 23.17   
Rfree (%) 27.66   
rmsd bond lengths (Å) 0.003   
rmsd bond angles (°) 0.572   
Ramachandran plot (%)    
    Most favored region 94.65   
    Additionally allowed  
    region 
5.02   
     Disallowed region 0.33   
     Clash score 3.42   
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Chapter 3: Biochemical characterization of Ssk1 point mutants 
Introduction 
To ensure that a crystal complex between Ssk1-R2-W638A with Ypd1 was 
physiologically relevant, functional properties of the W638A mutant were compared to 
WT Ssk1-R2.  Phosphotransfer was investigated from Ypd1 in vitro; phosphorylated 
lifetimes of Ssk1-R2~P in the presence and absence of Ypd1 were also tested.  Protein-
protein interaction affinities were measured with a fluorescence binding assay.  In 
almost every case Ssk1-R2-W638A behaved as WT.  Three notable anomalies were 
found.  In the fluorescence binding assay, the Ssk1-R2-W638A reversed the signal of 
Ypd1-T12C~F compared to WT (Figure 15 (pg. 45)).  A minor amount of the reverse 
phosphotransfer reaction from Ssk1-R2-W638A to Ypd1 was observed in vitro (Figure 
19 (pg. 49)). This reaction was not previously observed from WT Ssk1-R2~P to Ypd1 
under similar conditions.  Additionally, the phosphorylated lifetime of Ssk1-R2-W638A 
was extended 3-fold in the presence of Ypd1-H64Q (Figure 25 (pg. 53)). 
A structurally-guided investigation of mutations of other potentially important 
amino acid residues on Ssk1-R2 was carried out using the same methods of 
fluorescence binding and phosphotransfer assays.  Residues at the active site (Ssk1-R2-
Q556 and S612) were mutated to alanine to investigate the phospho-stabilization effect 
of Ypd1 on Ssk1-R2.  Residues that formed ionic interactions with Ypd1 in the Ssk1-
R2W638A/Ypd1 complex (absent from the Sln1-R1/Ypd1 complex; Ssk1-R2-R524, K525 
and H637) were mutated to alanine and evaluated in order to understand their 
contribution to binding affinity with Ypd1.  A description of the point mutants used as 
negative controls (Ssk1-D554N and I518S) along with point mutants that did not affect 
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Ssk1-R2/Ypd1 activity (Ssk1-R2-T631A, N635A and L636S) are also discussed.  Point 
mutants that are not presented in Ypd1 activity assays are given honorable mention 
(Ssk1-R2-D554A, V634S, L639S, E645Q, W646A, G647Q, and Q650L). 
Ssk1-R2-W638A retains wild type-like activity 
Affinity for Ypd1 
An in vitro fluorescence binding assay was used to measure relative affinities for 
Ypd1 and Ssk1-R2 and Ssk1-R2-W638A (For location of W638A, see Figure 12 (pg. 
35)).  A threonine at the edge of the Ypd1 hydrophobic binding patch was selected for 
the site of fluorescent labeling so that a binding event would be detected without 
interference (Figure 13 (pg. 44)).  Threonine 12 was mutated to cysteine (West lab, 
unpublished data) to make it amenable to chemical coupling with a fluorescent label (5-
iodoacetamidofluorescein (5-IAF), Figure 14 (pg. 44)).  Titrations of Ssk1-R2 and 
Ssk1-R2-W638A caused a change in the fluorescence signal produced by 5-IAF-labeled 
Ypd1-T12C in a concentration-dependent manner (Figure 15 (pg. 45), Figure 30 (pg. 
57)).  Calculation of dissociation constants revealed a minor but insignificant change in 
affinity between Ypd1 and Ssk1-R2-W638A (ΔΔGbinding = 0.93 kcal/mol). 
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Figure 13.  Molecular surface of Ypd1 showing the location of the T12C mutation.   
The mutation (shown in orange) at the periphery of the hydrophobic RR-binding patch1, 2 (shown in 
charcoal). 
 
 
Figure 14.  Chemical structure of 5-iodoacetamidofluorescein (5-IAF).  
Chemical conjugation takes place due to a nucleophilic substitution of the iodine by a reduced thiol group 
on Ypd1 cysteine 12. 
 
Binding curves were successfully fitted using a quadratic equation (Equation 1) 
to obtain dissociation constants.  However, the direction of the fluorescence signal was 
reversed in experiments using Ssk1-R2-W638A compared to WT.  The intrinsic 
fluorescence of Ssk1-R2 tryptophan (excitation at 280 nm and emission at 348 nm), in 
addition to π-π stacking, could influence the chemical environment of the 5-IAF 
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fluorophore causing a signal reversal.  Although the fluorescence signals are in opposite 
directions, only the magnitude of the change along with initial slope of the binding 
curve were used to determine binding affinity.  The dissociation constants with Ypd1-
T12C~F were calculated to be (25.1 ± 2.4) ± 1.3 nM for Ssk1-R2 (N=4) and (122.5± 
15.0) ± 36.7 nM for Ssk1-R2-W638A (N=3).  To verify that analysis was independent 
of signal direction, data points were artificially flipped across the x-axis, and curve 
fitting produced identical results. The observed ΔΔGbinding between Ssk1-R2-WT and 
Ssk1-R2-W638A was calculated to be 0.93 kcal/mol (Equation 2).  Although a slightly 
reduced affinity was seen for Ypd1-T12-C~F with Ssk1-R2-W638A, the difference in 
Kd values was considered insignificant
3.  
 
Figure 15.  Ssk1-R2-WT vs. Ssk1-R2-W638A fluorescence binding curves.   
Ssk1-R2 titration into Ypd1-T12C~F produces fluorescence quenching, while titration of Ssk1-R2-
W638A produces fluorescence enhancement.  Single experimental curves are shown as examples. 
 
Addition of Ssk1-R2 to Ypd1-T12C~F caused a quenching in the fluorescence 
signal, while addition of Ssk1-R2-W638A caused an enhancement (Figure 15).  This 
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change is likely due to the physical location of amino acid 638 on Ssk1-R2 relative to 
the site of fluoresceination on Ypd1.  W638 of Ssk1-R2 is in close proximity to the site 
of fluoresceination on Ypd1-T12C.  When tryptophan is modeled into the crystal 
structure in position 638 of Ssk1 to resemble Ssk1-R2-WT and cysteine is modeled in at 
residue 12 on Ypd1, the interatomic distance is approximately 9.3 Å (Figure 16).  Upon 
attachment of 5-IAF (~11 Å from end to end) to the cysteine, this gap would be bridged, 
allowing potential π-π stacking to occur during the WT interaction.  This could account 
for the quenching of the fluorescence signal upon the binding event.  The absence of the 
tryptophan ring in Ssk1-R2-W638A would remove any π-π stacking, resulting in a 
different chemical environment around the fluorescein.  This could explain the 
enhanced fluorescence observed upon Ssk1-R2-W638A binding to Ypd1-T12C~F. 
 
Figure 16.  Modeled distance between Ypd1-T12C and W638 in Ssk1-R2W638A.   
This figure shows Ypd1-T12C and W638 of Ssk1-R2 modeled in PyMol4.  The length of 5-IAF is ~11 Å 
from end to end.  When attached to Ypd1-T12C, 5-IAF could be in close enough proximity to W638 of 
Ssk1-R2 to allow π-π stacking.  (Mutations modeled on to Ssk1-R2W638A/Ypd1 co-crystal structure). 
 
Phosphotransfer activity with Ypd1 
Phosphotransfer from Ypd1~P to Ssk1-R2 reaches steady-state levels within 
seconds5.  In order to compare phosphotransfer efficiency between Ypd1 and Ssk1-R2-
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W638A, in vitro phosphotransfer experiments were performed.  The phosphotransfer 
efficiency for the Ssk1-R2-W638A mutant was comparable to WT (Figure 17 (pg. 47), 
Figure 31 (pg. 57)).   
 
Figure 17.  Phosphotransfer from Ypd1~P to Ssk1-R2 variants.   
Top panel shows phosphorimage of Ypd1~P phosphoryl transfer to Ssk1-R2 and Ssk1-R2-W638A within 
seconds that remained at a steady-state level after 5 minutes.  The negative control, unphosphorylatable 
mutant (Ssk1-R2-D554N), shows that the radiolabel remained on Ypd1.  Bottom panel shows protein 
load on 15% Coomassie-stained gel. 
 
In order to compare the phospho-stability of Ssk1-R2-W638A~P to WT, 32P-
labeled Ssk1 variants were monitored over time in the presence or absence of Ypd1.  
The phosphorylated half-lives of Ssk1-R2 and Ssk1-R2-W638A were determined to be 
23.6 ± 2.3 min and 22.1 ± 3.1 min, respectively (Figure 18 (pg. 48)).  Previously, the in 
vitro phosphorylated half-life of Ssk1-R2 was determined to be ~13 min6.  Differences 
in experimental image processing could account for the slight variation in 
phosphorylated half-life observed in this case compared to published data.  For 
example, previously published phorphorimages were obtained using autoradiography 
with an x-ray screen and current phosphorimages were obtained using a phosphor 
screen and a Typhoon (GE Healthcare) imager.  In addition, current images of 
radiolabeled bands were accurately quantified using ImageJ software.  When 
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phosphorylated Ssk1-R2-W638A was paired with Ypd1 using current methods, its half-
life was extended to ~ 40 hours (data not shown), comparable to the half-life of WT 
Ssk1-R2 in the presence of Ypd1 (using autoradiography)6.   
In conclusion, Ssk1-R2-W638A showed near-like WT activity with respect to 
affinity with Ypd1, phosphotransfer from Ypd1 and autodephosphorylation activity. 
 
Figure 18.  Phosphorylated half-lives of Ssk1-R2 and Ssk1-R2-W638A.   
Panel A shows all data points for phosphorylated half-life experiments for Ssk1-R2~P (black) and Ssk1-
R2-W638A~P (green) (experiments were done in quadruplicate).  Panel B is an example phosphorimage 
that shows the autodephosphorylation for Ssk1-R2~P and Ssk1-R2-W638A~P over 30 minutes.  
Calculated phosphorylated half-lives of 23.6 ± 2.3 min (Ssk1-R2) and 22.1 ± 3.1 min (Ssk1-R2-W638A) 
show that the autodephosphorylation reactions of the two proteins are similar. 
 
Although Ssk1-R2-W638A~P was stabilized by Ypd1 in a comparable manner 
to WT Ssk1-R2, the reverse phosphotransfer reaction was observed (Figure 19 (pg. 
49)).  This back-transfer has not been observed with WT Ssk1-R27 (Figure 23 (pg. 51)).  
In these experiments, back-transfer was detected by the appearance of a phosphorylated 
band corresponding to Ypd1, indicating that phosphotransfer from Ssk1-R2-W638A~P 
to Ypd1 had occurred.   
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Figure 19.  Phosphorimage of Ssk1-R2-W638A~P reverse phosphotransfer to 
Ypd1.   
Top panel shows phosphorimage and bottom panel shows protein load on a 15% Coomassie-stained gel.  
Lane 1: GST-HK~P + Ssk1-R2-W638A, Lanes 2-5: Ssk1-R2-W638A~P, Lanes 6-8: Ssk1-R2-W638A~P 
+ Ypd1.  Appearance of Ypd1~P bands in lanes 6-8 indicate phosphotransfer from Ssk1-R2-W638A to 
Ypd1. 
 
Ssk1-R2 active site mutants and phosphotransfer with Ypd1 
Protein purification 
Ssk1-R2 mutants were purified using the same protocol as WT Ssk1-R2 as 
described in Chapter 2.  Some mutants were subjected to an additional size-exclusion 
purification step (Figure 20).  Chitin column purifications of Ssk1-R2-Q556A and Ssk1-
R2-S612A are similar to WT (data not shown). 
 
Figure 20.  Ssk1-R2-Q556A Sephadex®-G75purification.   
Fractions 33-48 from a 100 mL gravity-flow gel filtration column showing a final purification step of 
Ssk1-R2-Q556A.  Gel shows a typical Ssk1-R2 protein yield of 1.5 mg/L. 
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Phosphotransfer activity with Ypd1 
To examine the activity of two residues that have been implicated in RR 
autodephosphorylation rates8-11, two point mutants were made: Ssk1-R2-Q556A 
(“D+2”) and Ssk1-R2-S612A (“T+2”).  Ssk1-R2-Q556 is located n+2 residues away 
from the phosphorylatable aspartate and Ssk1-R2-S612 is located n+2 residues away 
from the conserved switch threonine residue in the active site (Figure 21).   
 
Figure 21.  Illustration of the location of Ssk1-R2 active site point mutants.   
Surface and ribbon representation showing Ssk1-R2W638A (blue) mutation sites (cyan stick), Q556 
(“D+2”) and S612 (“T+2”) are shown. 
 
Phosphorylated half-lives were tested in the absence and presence of Ypd1.  
Reverse phosphotransfer from Ssk1-R2-Q556A~P to Ypd1 (Figure 22 (pg. 51)) was 
observed as in Ssk1-R2-W638A~P to Ypd1.  Reverse phosphotransfer from Ssk1-R2-
S612A~P was not observed as in WT (Figure 23 (pg. 51)). 
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Figure 22.  Phosphorimage of Ssk1-R2-Q556A~P reverse phosphotransfer to 
Ypd1.   
Top panel shows phosphorimage and bottom panel shows protein load on a 15% Coomassie-stained gel.  
Lane 1: GST-HK~P + Ssk1-R2-Q556A, Lanes 2-5: Ssk1-R2-Q556A~P, Lanes 6-8: Ssk1-R2-Q556A~P + 
Ypd1.  Appearance of Ypd1~P bands in lanes 6-8 indicate phosphotransfer from Ssk1-R2-Q556A to 
Ypd1. 
 
 
Figure 23.  Phosphorimages of Ssk1-R2-S612A and WT Ssk1-R2.   
The top panel shows a phosphorimage of Ssk1-R2-S612A~P without Ypd1 (lanes 1-4) and with Ypd1 
(lanes 5-8) over 1 hour.  The middle panel shows a phosphorimage of WT Ssk1-R2~P without Ypd1 
(lanes 1-4) and with Ypd1 (lanes 5-8) over 1 hour.  The bottom panel shows protein load of WT Ssk1-R2 
on a 15% Coomassie-stained gel (protein load for Ssk1-R2-S612A not shown). 
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Figure 23 (pg. 51) shows that autodephosphorylation of Ssk1-R2-S612A does 
not proceed as WT, but remains stable over 1 hour (N=2).  In contrast to Ssk1-R2-
W638A and Q556A, back-transfer from Ssk1-R2-S612A to Ypd1 was not observed.  
The phosphorimage shows that WT Ssk1-R2 dephosphorylated over time when Ypd1 is 
absent, but was stabilized in the presence of Ypd1, and back-transfer to Ypd1 was not 
observed, corroborating published data6, 7.   
Autodephosphorylation of Ssk1-R2-Q556A was measured (Figure 24) and 
compared to Ssk1-R2 and Ssk1-R2-W638A.  The calculated half-life was 23.7 ± 0.3 
min (N=3), showing no signifiant difference from WT or Ssk1-R2-W638A. 
 
Figure 24.  Dephosphorylation and half-life of Ssk1-R2-Q556A~P.   
Top panel shows dephosphorylation of Ssk1-R2-Q556A over 80 min.  Bottom panel is a phosphorimage 
of the gradual signal loss due to autodephosphorylation activity.  The calculated phosphorylated half-life 
of Ssk1-R2-Q556A~P was 23.7 ± 0.3 min (N=3), compared to 23.6 ± 2.3 min (Ssk1-R2) and 22.1 ± 3.1 
min (Ssk1-R2-W638A).  Results show no significant difference in the autodephosphorylation activity of 
these three proteins. 
 
 Since Ssk1-R2-W638A~P and Ssk1-R2-Q556A~P were able to transfer a 
phosphoryl group to Ypd1, their stabilities were tested in the presence of Ypd1-H64Q, a 
non-phosphorylatable Ypd1 mutant that would prevent the reverse phosphotransfer 
reaction from occurring.  Interestingly, the phosphorylated half-lives of both mutants 
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were extended >3-fold that of WT Ssk1-R2 in the presence of Ypd1-H64Q (Figure 25).  
When Ypd1-H64Q was paired with WT Ssk1-R2~P, the phosphorylated half-life was 
~2 hours, corroborating published data6,  while the phosphorylated half-life of Ssk1-R2-
W638A~P was extended to 6.1 ± 2.9 hours (N=2) and the phosphorylated half-life of 
Ssk1-R2-Q556A was extended to 6.5 ± 2.1 (N=2) hours (Figure 25). 
 
Figure 25.  Half-lives of Ssk1-R2-Q556A~P and Ssk1-W638A~P with Ypd1-H64Q 
compared to WT Ssk1-R2.   
A)  The natural log of the percentage of remaining radiolabel on each Ssk1-R2 variant over ~25-45 hours.  
B)  Phosphorimages of Ssk1-R2~P variants showing the decay of radiolabel over 8 hours (marker lanes 
have been removed for clarity).  C)  15% Coomassie-stained gel showing protein load of the Ssk1-R2-
W638A~P panel B experiment as an example (protein load of WT Ssk1-R2 and Ssk1-R2-Q556A not 
shown). 
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Negative control mutants of Ssk1-R2 
Point mutants of Ssk1-R2 (Figure 26) were constructed to act as negative 
controls in phosphotransfer and fluorescence binding assays.  The first mutants 
constructed were the unphosphorylatable mutants, Ssk1-R2-D554N and Ssk1-R2-
D554A (C-terminal end of β3).  Ssk1-R2-I518S (α1 helix), was made to disrupt the 
formation of the Ypd1/Ssk1-R2 complex by interfering with the hydrophobic docking 
site interaction.  The reasons for choosing the I518 residue as a control mutant were 2-
fold:  before the co-crystal structure was solved, a sequence alignment indicated that 
I518 occupied the same position as V1102 in Sln1-R1, which is an essential 
hydrophobic interface contact with Ypd112.  This position was predicted to have the 
same significance in the Ssk1-R2/Ypd1 complex.  Additionally, when I518 was mutated 
to a polar residue (threonine), Ypd1 association was disrupted in vivo13.   
 
Figure 26.  Illustration of the location of Ssk1-R2 negative control point mutants.   
Surface and ribbon representation showing Ssk1-R2W638A (blue) mutation sites (cyan stick), D554 
(phosphorylatable aspartate, β3) and I518 (essential hydrophobic contact point, α1) are shown. 
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Protein purification 
Ssk1-R2-D554N (Figure 27), D554A (data not shown) and I518S (Figure 28) 
were purified using the same protocol as WT Ssk1-R2 as described in Chapter 2. 
 
Figure 27.  Chitin column purification of Ssk1-R2-D554N.   
M- marker, 1- loaded chitin resin for Ssk1-R2-D554N, 2- chitin resin after βME incubation and elution of 
cleaved Ssk1-R2-D554N protein, 3-4- elutions of Ssk1-R2-D554N. 
 
Figure 28.  Chitin column purification of Ssk1-R2 and Ssk1-R2-I518S.   
M- marker, 1- loaded chitin resin for Ssk1-R2-WT, 2- chitin resin after βME incubation and elution of 
cleaved Ssk1-R2-WT protein, 3- elution of Ssk1-R2-WT, 4- loaded chitin resin for Ssk1-R2-I518S, 5- 
chitin resin after βME incubation and elution of cleaved Ssk1-R2-I518S protein, 6- elution of Ssk1-R2-
I518S.  Gel illustrates that the purification of Ssk1-R2-I518S is similar to WT purification. 
 
An alternative mutant (Ssk1-R2-V634S) was selected to disrupt the Ssk1-
R2/Ypd1 binding interface based on an Sln1-R1 sequence alignment, but due to 
insolubility, purification attempts were abandoned (Figure 29 (pg. 56)). 
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Figure 29.  Purification of Ssk1-R2-V634S.   
M- marker, 1- uninduced BL21-Star cells, 2- induced BL21-Star cells, 3- supernatant of whole cell lysate, 
4- pellet of whole cell lysate, 5- loaded chitin resin, 6- chitin resin after βME incubation and elution of 
cleaved protein, 7- elution of Ssk1-R2-V634S.  Gel illustrates that the Ssk1-R2-V634A mutant did not 
yield purified protein.  
 
Binding affinity and phosphotransfer activity with Ypd1 
The D554N mutant did not display significantly different affinity for Ypd1 in 
the fluorescence binding assay (Table 5 (pg. 63), Figure 30 (pg. 57)), but as expected, 
was unable to accept a phosphoryl group from Ypd1~P in a phosphotransfer assay 
(Figure 17 (pg. 47) and Figure 31 (pg. 57)).   
 The I518S mutation completely abolished Ypd1 binding in the fluorescence 
binding assay (Figure 30 (pg. 57)).  It also demonstrated a greatly diminished ability to 
accept a phosphoryl group from Ypd1~P in a phosphotransfer assay (Figure 31 (pg. 
57)).   
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Figure 30.  Initial portion of fluorescence binding curves.   
Initial portions of equilibrium binding curves from Ssk1-R2, Ssk1-R2-W638A, Ssk1-D554N and Ssk1-
I518S titrated in to 6 nM Ypd1-T12C~F.  Curves for Ssk1-R2, Ssk1-R2-D554N and Ssk1-R2-I518S were 
mathematically adjusted to begin at the origin and have a positive slope in order to highlight the 
magnitude of fluorescence signal change.  Ssk1-R2-W638A was not adjusted, as it naturally produced an 
enhanced fluorescence signal. 
 
 
Figure 31.  Phosphorimage of Ypd1~P phosphotransfer to Ssk1-R2 variants.   
The image shows that Ypd1~P transfers a phosphoryl group to Ssk1-R2 (100%) and Ssk1-R2-W638A 
within seconds.  Ssk1-R2-D554N is not able to accept a phosphoryl group and the phospho-accepting 
activity of Ssk1-R2-I518S is greatly diminished, with most of the radiolabel remaining on Ypd1. 
 
Ssk1-R2-I518S was able to accept a phosphoryl group from an artificial 
upstream donor, the HK domain from Sln1 (Figure 32 (pg. 58)).  Although the transfer 
was not efficient and most of the radiolabel remains on HK, the transfer ability indicates 
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that Ssk1-R2-I518S is able to be phosphorylated in a limited manner, suggesting that it 
retains proper tertiary structure. 
 
Figure 32.  Ssk1-R2-I518S is able to accept a phosphoryl group from GST-HK~P.   
Left panel shows phosphorimage of Ssk1-R2-I518S accepting a phosphoryl group from GST-HK~P.  
Right panel shows protein load on a15% Coomassie-stained gel. 
 
Abolishment of salt bridge formation affects binding affinity 
 Due to the physiological role of the Ssk1/Ypd1 interaction as part of the osmotic 
stress response6, 14 and in vitro reaction to osmolyte concentrations15, electrostatic 
interactions were examined as a possible explanation for the functional differences of 
Sln1-R1/Ypd1 and Ssk1-R2/Ypd1.  Interface analysis was performed on the co-crystal 
structure of Ssk1-R2W638A/Ypd1 and revealed two additional intermolecular salt bridges 
(Ssk1-R2-R524/Ypd1-D24 and Ssk1-R2-K525/Ypd1-D23) and one possible ionic 
interaction (Ssk1-R2-H637/Ypd1-E16) when compared to the Sln1-R1/Ypd1 co-crystal 
complex (Figure 33 (pg. 59)). 
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Figure 33.  Molecular surfaces illustrating salt bridge locations of Sln1-R1 and 
Ssk1-R2W638A and Ypd1. 
Complexes have been pulled apart and rotated 90° in order to directly view interfaces.  A) Ssk1-R2W638A 
(blue) and Ypd1 (green).  B) Sln1-R1 (yellow) and Ypd1 (green) (PDB ID: 1OXB).  Observed salt bridge 
interactions are shown in magenta.  Sln1-R1/Ypd1 interface contains one double salt bridge at the active 
site while the Ssk1-R2W638A/Ypd1 interface contains ionic interaction patches surrounding the 
hydrophobic docking site.   
 
Protein purification 
Ssk1-R2-R524A, K525A and H637A were purified using the same protocol as 
WT Ssk1-R2 as described in Chapter 2 (Figure 34 (pg. 60)). 
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Figure 34.  Chitin column purification gels of Ssk1-R2-R524A, Ssk1-R2-K525A 
and Ssk1-R2-H637A.   
M- marker;  Lanes 1, 4, 7- loaded chitin resin; Lanes  2, 5, 8- chitin resin after βME incubation and 
elution of cleaved Ssk1-R2-WT protein; Lanes 3, 6, 9- protein elution. 
 
Binding affinity between Ssk1-R2 salt bridge mutants and Ypd1 
 Ssk1-R2 point mutations were constructed to abolish the unique ionic 
interactions at the Ssk1-R2/Ypd1 interface.  Ssk1-R2-R524, K525 and H637 were 
mutated to alanine and tested in the fluorescence binding assay with Ypd1-T12C~F.  
Binding to Ypd1 was significantly reduced with R524A and K525A and insignificantly 
reduced with H637A3 (Figure 35, Table 4 (pg. 61)).  At the concentrations tested, Ssk1-
R2-R524 and Ssk1-R2-K525 produced linear curves, indicating that binding with Ypd1-
T12C~F was not saturated.  Without a hyperbolic binding curve, accurate dissociation 
constants could not be calculated.  From examination of preliminary data, dissociation 
constants for both mutants are > 0.5 µM.  In addition, a double mutant (Ssk1-R2-
R524A/H637A) showed a markedly decreased affinity for Ypd1-T12C~F (data not 
shown). 
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Figure 35.  Fluorescence binding assay of Ssk1-R2 mutants with Ypd1-T12C~F. 
Hyperbolic binding curves indicate strong binding (low nanomolar Kd) while linear binding curves (Ssk1-
R2-R524A and Ssk1-R2-K525A) signify that Kds are so high that they cannot be calculated because 
binding saturation has not been reached.  A dissociation constant was calculated only for Ssk1-R2-
H637A.  (Ssk1-R2-W638A is shown as a positive control.)  These results illustrate the reduced binding 
affinity with Ypd1 by mutating basic residues R524 and K525 on Ssk1-R2 to alanine. 
 
Table 4.  Dissociation constants of Ssk1-R2 salt bridge point mutants.   
Entropic contributions were assumed constant when calculating observed ΔΔGbinding for each mutant. 
Ssk1-R2 variant 
Observed Kd with 
Ypd1-T12C~F 
(Kd ± mean error) ± 
standard error of mean 
Observed 
ΔΔGbinding 
(kcal/mol) 
WT (25.1 ± 2.4) ± 1.3 nM 0 
R524A N/D n/a 
K525A N/D n/a 
H637A (129.6 ± 4.9) nM 0.97 
 
Although mutating salt bridge residues on Ssk1-R2 disrupted affinity for Ypd1 
in the fluorescence binding assay, they did not abolish phosphotransfer to Ssk1-R2, nor 
did they shift the preference of Ypd1 to phosphorylate Ssk1-R2 over Skn7-R3 (Figure 
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36).  Qualitatively, there was more radiolabel present after 5 minutes on all Ssk1-R2 
variants than on Skn7-R3 (approximate equimolar load, data not shown).   
Phosphotransfer activity with Ypd1 
 
Figure 36.  Ypd1~P phosphotransfer to Ssk1-R2 variants vs. WT Skn7-R3.   
Phosphorimage shows phosphorelay through the entire Sln1 pathway.  Sln1-HK  Sln1-R1  Ypd1   
Ssk1-R2 or Skn7-R3. 
 
Mutations that do not affect Ssk1-R2 activity 
 Before the co-crystal structure was solved, Ssk1-R2 mutants were constructed to 
test the effects of binding with Ypd1.  The following mutants did not significantly affect 
binding with Ypd1-T12C~F in the fluorescence assay: D554N, S612A, T631A, N635A, 
L636S (purifications not shown) (Figure 37 (pg. 63)).  When tested in the fluorescence 
binding assay, these mutants retained a low nanomolar dissociation constant with Ypd1, 
similar to WT Ssk1-R2 (Table 5).  A significant observed ΔΔGbinding was considered to 
be >1 kcal/mol3.  When titrated into Ypd1-T12C~F in the fluorescence binding assay, 
all mutants produced a quenching effect of the fluorescence signal, supporting the 
hypothesis that W638 is responsible for this effect.  Other mutants that were created but 
not tested due to their distal positions with respect to the interface in the final co-crystal 
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structure were L639S, E645Q, W646A, G647Q, and Q650L (purifications not shown) 
(Figure 37). 
 
Figure 37. Illustration of Ssk1-R2 mutants that did not affect Ypd1 binding.   
Ribbon representation of point mutants (stick, cyan) are shown on Ssk1-R2W638A (blue).  Ypd1 is shown 
in green. 
 
Table 5.  Kd values of Ssk1-R2 point mutants that did not affect Ypd1 binding. 
Minimum number of replicates (N=3). Entropic contributions were assumed constant when calculating 
observed ΔΔGbinding for each mutant.   
Ssk1-R2 variant 
Observed Kd with 
Ypd1-T12C~F 
(Kd ± mean error) ± 
standard error of mean 
Observed 
ΔΔGbinding 
(kcal/mol) 
WT (25.1 ± 2.4) ± 1.3 nM 0 
W638A (122.5± 15.0) ± 36.7 nM 0.93 
D554N (71.1 ± 6.2) ± 4.9 nM 0.61 
Q556A (75.9 ± 1.6) ± 1.0 nM 0.65 
S612A (22.9 ± 1.9) ± 1 nM -0.05 
L636S (18.7 ± 1.6) ± 1.5 nM -0.17 
N635A (14.3 ± 1.0) ± 0.6 nM -0.33 
T631A (14.3 ± 1.5) ± 1.6 nM -0.33 
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Discussion 
 Ssk1-R2-W638A was not significantly altered from WT activity with respect to 
Ypd1 binding affinity, phospho-accepting ability, or autodephosphorylation activity, 
suggesting that the co-crystal structure likely represents a physiologically relevant 
complex.   
However, Ssk1-R2-W638A~P exhibited minor back-transfer to Ypd1 in vitro.  
Active site mutant Ssk1-R2-Q556A~P displayed the same reversible transfer to Ypd1.  
Since neither Ssk1-W638A nor Q556A significantly altered the ability to bind to Ypd1, 
these results indicate that W638 and Q556 of Ssk1 could play a role in stabilizing the 
strongly-favored unidirectional Sln1 pathway.  Ssk1-R2-S612A did not show reversible 
phosphotransfer to Ypd1, but it did not retain WT-like autodephosphorylation like the 
Ssk1-R2-Q556A mutant.  Since it also did not alter Ypd1 binding, it is likely that 
residue S612 of Ssk1 does not play a role in the apparent irreversibility of the 
phosphotransfer reaction, but may be implicated in affecting autodephosphorylation of 
Ssk1-R2. 
Since both Ssk1-R2-W638A~P and Q556A~P showed back-transfer to Ypd1, 
quantifying the phospho-stabilization by Ypd1 could not be done accurately.  Instead, 
the non-phosphorylatable Ypd1-H64 mutant was used.  In published WT Ssk1-R2 
assays, the half-life of Ssk1-R2~P in the presence of Ypd1 is ~40 hours and ~2 hours in 
the presence of Ypd1-H64Q6.  Compared to WT, both Ssk1-R2-W638A and Ssk1-R2-
Q556A displayed 3-fold extended phosphorylated half lives in the presence of Ypd1-
H64Q.   
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Ssk1-R2-I518S served as a suitable negative control in the fluorescence assay by 
disrupting binding with Ypd1-T12C~F, which was reflected in a phosphotransfer assay 
with Ypd1.  Ssk1-R2-D554N was a reliable control for the phosphotransfer assay due to 
its inability to accept a phosphoryl group without disrupting binding to Ypd1, per the 
fluorescence binding assay. 
Guided by the co-crystal structure, two ionic interactions were found to play an 
important role in the affinity of Ypd1 and Ssk1-R2.  Ssk1-R2-R524/Ypd1-D24 (2.6 Å) 
along with Ssk1-R2-K525/Ypd1-D23 (3.5 Å) formed an adjacent double salt bridge at 
the interface of Ypd1 (αA-αB loop) and Ssk1-R2W638A (α1 helix) (Figure 38).   
 
Figure 38.  Ribbon and stick illustration of salt bridge interactions.   
Ypd1 (green) D23 and D24 on the αA-αB loop forms two contiguous salt bridges with Ssk1-R2W638A 
(blue) K525 and R524 on the α1 helix, respectively. 
 
Although Ssk1-R2-R524A and Ssk1-R2-K525A played an important role in 
binding affinity with Ypd1, the mutants did not disrupt phosphotransfer from Ypd1~P 
in vitro, nor alter the preference of Ypd1 to phosphorylate Ssk1-R2 over Skn7-R3.  
These single ionic mutations disrupted binding in the fluorescence assay, but did not 
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completely abolish the Ypd1-Ssk1-R2 interaction. This leads me to believe that both 
salt bridges must be disrupted at once to see an abolishment that would be reflected in 
phosphorelay from Ypd1.  Since Ssk1-R2-R524 and K525 form a contiguous salt bridge 
patch, a double mutant was constructed and verified with DNA sequencing (Ssk1-R2-
R524A/K525A) to abolish both interactions.  Unfortunately, this mutant would not 
transform into expression cells and could not be evaluated.  The double-abolishment 
would likely have a greater impact on binding affinity and phosphotransfer with Ypd1.  
In the future, this hypothesis could be tested by using a single point mutant from Ssk1-
R2 (e.g. Ssk1-R2-R524A) and a single point mutant from Ypd1 (e.g. Ypd1-D23A) to 
abolish both ionic interactions. 
Experimental Section 
Construction of mutants 
All Ssk1-R2 mutants were created by QuikChange mutagenesis (see Appendix 
A) from the wild-type plasmid in a hybrid pET11a/pCYB2 vector.  Double and triple 
mutants (Ssk1-R2-R524A-K525A and Ssk1-R2-R524A-K525A-H637A) were 
constructed and confirmed by DNA sequencing.  They could not be transformed into 
expression cells and were not able to be evaluated.  For most of the point mutants, with 
the exception of V634S (insoluble) and W638A (increased solubility), purification was 
identical to WT Ssk1-R2 and produced soluble protein with a similar yield (1-2 mg/L). 
Transformation 
Transformations were carried out by incubating nanogram quantities of plasmid 
DNA with competent E. coli cells (50-250 µL) on ice for 30 minutes followed by a 30-
45 second heat-shock at 42 °C.  After cooling cells on ice for 2-5 minutes, LB or SOC 
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was added to the reaction up to 500-1000 µL and cells were incubated for 60 minutes, 
200 rpm, 37 °C.  Cells were plated on LB + ampicillin and incubated overnight at 37 
°C.   
Protein purification 
Ssk1-R2 mutants were purified using the IMPACT (NEB) system as described 
in Chapter 2.  For phosphotransfer and fluorescence binding assays, 1 mL or 500 µL 
elutions from chitin columns were sufficiently pure.  In some cases, proteins were 
further purified by size-exclusion chromatography (Sephadex®-G75).  Proteins were 
generally flash-frozen in an ethanol/dry ice bath directly from the chitin columns and 
stored at -20 °C until ready for use.   
Phosphotransfer experiments 
Phosphotransfer from Ypd1 to Ssk1-R2 variants was measured as described 
previously16 with minor modifications.  Resin-bound glutathione S-transferase (GST)-
HK-Sln1-R1 was incubated in 50 mM Tris pH 8.0, 100 mM KCl, 10 mM MgCl2, 2 mM 
dithiothreitol (DTT) and 20% glycerol with 5-10 μCi (17-34 nM) [γ-32P]ATP (Perkin 
Elmer, BLU002A250UC, 3000 Ci/mmol) and ~25 μM ATP for 30 minutes in 50-100 
μL reactions for autophosphorylation.  Next, Ypd1 (35 μM) was added for 5 minutes. 
The reaction was filter-centrifuged to remove resin-bound phospho-donor (0.45 µm 
filter) and the supernatant (Ypd1~P) was removed and transferred into a 50 μL solution 
of equimolar Ssk1-R2 variant (50 mM Tris pH 8.0, 100 mM KCl, 15 mM MgCl2, 2 mM 
DTT).  Aliquots were removed at various time points and added to 1X stop buffer (0.25 
M Tris pH 6.8, 8% SDS, 60 mM EDTA, 40% glycerol, and 0.008% bromophenol blue) 
to quench reactions.  Samples were separated on 15% SDS-PAGE gels and analyzed 
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with a Typhoon phosphorimager (GE Healthcare).  Gels were stained in Coomassie 
stain and each phosphorimage band and Coomassie-stained gel was quantified using 
ImageJ17.  When phosphorylation levels were quantified, each radio label signal was 
normalized with its corresponding Coomassie protein band to correct for any loading 
inconsistencies.  The radiolabel signals were compared to each other to determine 
efficiency. 
Phosphorylated half-life experiments were conducted as reported previously5 
with the only modification being the use of [γ-32P]ATP with higher specific activity 
(Perkin Elmer, BLU002A250UC, 3000 Ci/mmol).  GST-Sln1-HK and the Ssk1-R2 
variant (100 µL) were incubated for 90 minutes in 50 mM Tris pH 8.0, 100 mM KCl, 
10 mM MgCl2, 2 mM DTT and 20% glycerol with 10 μCi (~30-70 nM) [γ-32P]ATP.  
The reaction was filter-centrifuged to remove resin-bound phospho-donor (0.45 µm 
filter) and the supernatant (Ssk1-R2~P) was removed and transferred into a 5 μL 
solution of equimolar Ypd1, Ypd1-H64Q or buffer (50 mM Tris pH 8.0, 100 mM KCl, 
15 mM MgCl2, 2 mM DTT).  Aliquots were removed at various time points and added 
to 1X stop buffer (0.25 M Tris pH 6.8, 8% SDS, 60 mM EDTA, 40% glycerol, and 
0.008% bromophenol blue) to quench reactions.  Samples were flash-frozen as needed 
and stored at -20 °C until all aliquots were ready for analysis.  Samples were separated 
on 15% SDS-PAGE gels and exposed to a storage phosphor screen (GE Healthcare) 
overnight.  The screens were analyzed with a Typhoon phosphorimager (GE 
Healthcare) and processed with ImageJ17.  Gels were Coomassie-stained to determine 
protein load.  Rate constants for the dephosphorylation of Ssk1-R2 variants and half-
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lives were determined by least-squares fitting of the natural logarithm of the data to a 
linear relationship assuming first-order kinetics as previously published6. 
Fluorescence binding affinity 
Ypd1-T12C was purified and buffer-exchanged into 50 mM Tris-HCl pH 9.0 
with 100 mM NaCl with 5-fold molar excess of Tris-(2-carboxyethyl)phosphine-HCl 
(TCEP) to keep the reaction in a reduced environment.  The protein was incubated in 
darkness for 2 hours at room temperature with a 7-fold molar excess of 5-IAF for 
covalent labeling on the exposed cysteine.   Unincorporated 5-IAF was removed using 
size-exclusion chromatography (50 mL Sephadex®-G25 column at pH 8.0).  Labeling 
efficiency of Ypd1-T12C was 71%.  Labeled Ypd1-T12C (Ypd1-T12C~F) was 
aliquoted and stored in the presence of 10% glycerol at -20 ˚C until ready for use.   
Before beginning the assay, proteins were thawed and equilibrated to room 
temperature.  Fluoresceinated Ypd1-T12C was added to a quartz fluorescence cuvette 
containing a reaction buffer of 50 mM Tris-HCl pH 8.0, 10 mM MgCl2, and 1 mM DTT 
in a total volume of 2.5 mL.  All assay buffers were passed through a 10 mL Chelex® 
(BioRad) column to remove trace metal impurities before use. Ssk1-R2 variants were 
titrated into the cuvette in 2-20 μL increments to a final volume of 2.7 mL.  The 
reaction was constantly stirred slowly with a magnetic stir bar and allowed to 
equilibrate for 20 seconds.  The fluorescence intensity was measured with each addition 
of Ssk1-R2 variant in order to generate an equilibrium binding curve.  Ssk1-R2 
concentrations were optimized for each assay and the Ypd1-T12C~F concentration was 
kept constant at 6, 15 or 30 nM.  Assays were designed in such a way that the 
concentration of the first addition of the Ssk1-R2 variant started below the 
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concentration of Ypd1-T12C~F and gradually increased in order to bracket the expected 
Kd. For Ssk1-R2-W638A, titrations spanned 10-1300 nM.  For Ssk1-R2 and other 
mutants, titrations spanned 3-300 nM.  The 5-IAF tag attached to Ypd1-T12C was 
excited at 488 nm and emission was observed at 515 nm (Fluoromax-4 
Spectrofluorometer from Horiba Scientific, excitation and emission slit widths set to 5 
nm, 23 °C).  The fluorescence intensity measurements were corrected for volume before 
data analysis. Fractional fluorescence was calculated (F/F0) and response curves were 
adjusted to begin at the origin and increase ((F/F0-1) for Ssk1-R2-W638A; (1-F/F0) for 
all other Ssk1-R2 variants).  Kaleidagraph was used to program an expanded quadratic 
equation to fit data and calculate dissociation constants (Equation 1).  ΔΔGbinding was 
determined by assuming entropic contributions were constant (Equation 2). 
Equation 1.  Quadratic equation used to analyze fluorescence binding data. 
 
𝐹𝑇 = 𝐹𝐵 (
(𝐾𝑑+[𝐴𝑇]+[𝐵𝑇])±√(𝐾𝑑+[𝐴𝑇]+[𝐵𝑇])2−4[𝐴𝑇][𝐵𝑇]
2
) +
𝐹𝐹 ([𝐵𝑇] − (
(𝐾𝑑+[𝐴𝑇]+[𝐵𝑇])±√(𝐾𝑑+[𝐴𝑇]+[𝐵𝑇])2−4[𝐴𝑇][𝐵𝑇]
2
))  
 
[𝐴𝑇] = [Ssk1 − R2], 𝑥 variable;  [𝐵𝑇] = [Ypd1]; 𝐾𝑑 = dissociation constant;  𝐹𝐵 =
fluorescence of bound protein;  𝐹𝐹 = fluorescence of free protein; 𝐹𝑇 =
total fluorescence; [𝐵𝑇] <  𝐾𝑑    
 
Equation 2.  Equation to calculate ΔΔGbinding between Ssk1-R2 and mutants with 
Ypd1-T12C~F. 
[
𝑅𝑇(ln 𝐾𝑑)
4184 J
]
𝑊𝑇
−   [
𝑅𝑇(ln 𝐾𝑑)
4184 J
]
𝑚𝑢𝑡𝑎𝑛𝑡
 
𝑅 = gas constant (8.314462 J ∙ K−1mol−1;  𝑇 = temperature (296 K)   
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Chapter 4: Insights gained from the co-crystal structure of Ssk1-
R2W638A/Ypd1 
 
Introduction 
Ypd1 has shown preference for Ssk1-R2 in phosphotransfer experiments1, 
exhibited a three-fold increase in affinity for Ssk1-R2 over Sln1-R1 in yeast two-hybrid 
experiments2, showed a ~1000-fold increase over Sln1-R1 in binding affinity in the 
fluorescence binding assay (West lab, unpublished data) and is known to stabilize 
phosphorylated Ssk1-R2 in vitro3.  This evidence indicates that Ypd1 likely forms a 
strong-transient complex with Ssk1-R2, while forming a weak-transient complex with 
its upstream cognate partner, Sln1-R14, 5.  These differences are likely essential to the 
cell in order to maintain the function of the Sln1 stress response pathway.  Ypd1~P 
constitutively phosphorylates Ssk1 to maintain homeostasis during unstressed periods6 
while the unphosphorylated Ssk1 dimer accumulates in the cell to activate the HOG1 
pathway in times of hyperosmotic stress7.  Since Sln1-R1 and Ssk1-R2 dock with Ypd1 
on a common hydrophobic docking patch2 using many of the same contacts, structural 
differences between the receiver domains of Sln1 and Ssk1 along with their interactions 
with Ypd1 must be responsible for their distinct biological roles. 
In order to elucidate the structural basis for the differences in physiological 
function, this chapter compares and contrasts the individual receiver domain structures, 
rigid body docking positions with Ypd1, interface contacts with Ypd1 and the active 
site geometries of Sln1-R1 and Ssk1-R2W638A.  This chapter also brings together the 
biochemical data collected from Ssk1-R2 point mutants and discusses the possible 
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physiological implications to the Sln1 pathway and questions that still remain 
unanswered. 
Comparison of Ssk1-R2W638A/Ypd1 and Sln1-R1/Ypd1 complexes 
Direct comparison of the structures of Sln1-R1 and Ssk1-R2W638A show that they 
retain the same conserved (βα)5 topology.  Structural alignment of the receiver domains 
of Sln1 and Ssk1W638A shows an overall rmsd of 0.915 Å using sequence-independent 
superpositioning (Figure 39, panel B (pg. 75)).  One notable difference is a ~20 residue 
loop extending from α3 to β4 on the distal end of Ssk1 that is absent in Sln1.   In the 
Ssk1-R2W638A/Ypd1 crystal structure, electron density was not observed for 15 residues 
of this loop, suggesting that this region is highly flexible.  In addition, the construct of 
Ssk1-R2W638A contains a 50-residue C-terminal tail with no observable electron density, 
suggesting high flexibility and lack of ordered structure.   
Although there is high tertiary structure similarity (<1 Å rmsd), the receiver 
domains are not identical (Figure 39, panel C (pg. 75)).  The largest differences appear 
on the side of the receiver domain distal to the Ypd1 interface.  For example, the C-
terminal end of the α1 helix is shifted 4.2 Å in Ssk1-R2W638A.  Additionally, the α3 helix 
in Ssk1-R2W638A extends 6.9 Å further than the α3 helix in Sln1-R1.  In Sln1-R1, the 
α2-β3 loop extends 7.4 Å beyond the α2-β3 loop in Ssk1-R2W638A.  These differences 
may or may not affect the Ypd1 interaction, but since they are not located at the 
interface, it is unlikely that these differences play a central role. 
The high conservation in tertiary structure between Sln1-R1 and Ssk1-R2W638A 
and the shared Ypd1 binding site suggest that the receiver domains may interact with 
Ypd1 in approximately the same orientation.  Comparison of the co-crystal structures 
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show that this is not the case.  A rigid body movement of the receiver domain docking 
positions on Ypd1 is apparent (Figure 39, panel A).  This indicates that the interfaces 
between Ypd1 and its cognate receiver domains are distinct, at least in the 
unphosphorylated state. 
 
 
Figure 39.  Structural comparison of Sln1-R1 and Ssk1-R2W638A with Ypd1.   
A) Sln1-R1 (yellow, PDB ID: 1OXB) and Ssk1-R2W638A (blue) interface with Ypd1 (green) at the same 
hydrophobic docking site but have different rigid body positions. B) Sln1-R1 (yellow, PDB ID: 1OXB) 
superpositioned with Ssk1-R2W638A (blue).  The sites of phosphorylation (Sln1-R1-D1144, Ssk1-R2-
D554) are shown as sticks.  C) Sln1-R1 and Ssk1-R2 structure-based sequence alignment performed with 
UCSF Chimera8.  Secondary structure is indicated above the sequence (β-strands are arrows, α-helices are 
ribbons). 
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Comparison of Ssk1-R2W638A/Ypd1 and Sln1-R1/Ypd1 interfaces 
In 2008, Horie et al.7 described mutants of Ssk1-R2 (E510G, N512T, I514T, and 
I518T) that abolished interactions with Ypd1 in vivo.  The co-crystal structure strongly 
corroborates that data by demonstrating that these residues play important roles in Ypd1 
complex formation.  N512 on Ssk1-R2W638A is a central interfacial residue.  It forms 
hydrogen bonds with Q38 and S69 of Ypd1 along with a hydrophobic contact to F65.  
I514 is involved in a hydrophobic contact with F35 of Ypd1, while I518 is involved in 
hydrophobic contacts with L31, I17 and A72 of Ypd1.  E510 is a highly conserved 
active site residue that participates in coordination of the divalent metal cation required 
for proper side chain geometry during the phosphotransfer event. It does not directly 
contact Ypd1 in the complex structure, but it does appear to stabilize N515 through an 
intramolecular salt bridge (4.0 Å).  This asparagine forms a hydrophobic contact with 
A72 and G68 of Ypd1.   
In addition to corroborating in vivo data, the structure also confirms that Ypd1 
uses the same hydrophobic patch2 to interact with Sln1-R1 and Ssk1-R2.  Although the 
area of interaction on Ypd1 is the same, the rigid body docking positions are different 
and there are many unique contacts at the Ssk1-R2W638A/Ypd1 interface (Table 6). 
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Table 6.  Interface contacts in Sln1-R1/Ypd1 and Ssk1-R2W638A/Ypd1. 
Ypd1 Residue Location Sln1-R1 Residue(s) Location 
Ssk1-R2W638A 
Residue(s) 
Location 
Interactions that are similar in Sln1-R1/Ypd1 (PDB 1OXB) and Ssk1-R2W638A/Ypd1 
Hydrophobic 
interactions      
ILE13 αA PRO1196 β5-α5 loop PRO633 β5-α5 loop 
ILE17 αA VAL1102 α1 ILE518 α1 
MET20 αA LEU1109 α1 LYS525 α1 
PHE27 αB ARG1105 α1 SER521 α1 
LEU31 αB VAL1102, VAL1098 α1 ILE518, ILE514 α1 
SER69 αC VAL1098 α1 ILE514 α1 
ALA71 αC PRO1196 β5-α5 loop PRO633 β5-α5 loop 
ALA72 αC PRO1196, VAL1102 β5-α5 loop, α1 PRO633, ILE518 β5-α5 loop, α1 
      
Hydrogen 
bonds      
GLN38 Oε1 αB ASN1096 Nδ2 β1-α1 loop ASN512 Nδ2 α1 
GLN38 Nε2 αB ASN1096 Oδ1 β1-α1 loop ASN512 Oδ1 α1 
PHE65 O αC ASN1096 Nδ2 β1-α1 loop ASN512 Nδ2 α1 
GLY68 O αC ASN1099 Nδ2 α1 ASN515 Nδ2 α1 
      
Salt bridges 
     
HIS64 Nε2 αC ASP1095 Oδ2 β1-α1 loop ASP511 Oδ2 β1-α1 loop 
      
Interactions that are unique between Sln1-R1/Ypd1 (PDB 1OXB) and Ssk1-R2W638A Ypd1 
 
Hydrophobic 
interactions      
ILE13 αA LYS1198 α5 
  
ILE17 αA 
  
LEU636 α5 
MET20 αA ARG1105, MET1106 α1 ILE518, LEU636 α1, α5 
PHE27 αB VAL1102 α1 ALA517 α1 
LEU31 αB 
  
ALA517 α1 
PHE35 αB 
  
ILE514 α1 
ALA72 αC VAL1098 α1 
  
LEU73 αC VAL1098 α1 ILE514, ILE518 α1 
GLU83 αD PHE1175 β4-α4 loop 
  
      
Hydrogen 
bonds      
GLU16 Oε1 αA ARG1199 N α5 HIS637 N α5 
GLU16 Oε2 αA 
  
ASN635 Nδ2, N α5 
MET20 O αA ARG1105 Nη2 α1 
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ASP24 Oδ2 
αA-αB 
loop   
ARG524 Nη1 α1 
GLN34 Oε1 αB HIS1097 Nδ1 α1 
  
GLN34 Nε2 αB GLU1101 Oε2 α1 
  
ASP60 Oδ1 αC GLN1146 Nε2 β3-α3 loop 
  
ASN61 Oδ1 αC GLN1146 Nε2 β3-α3 loop 
  
HIS64 Nε2 αC 
ASP1095 Oδ2, 
GLN1146 O 
β1-α1 loop, β3-
α3 loop   
SER69 N αC ASN1099 Oδ1 α1 
  
SER69 Oγ αC 
  
ASN512 Nδ2 α1 
ARG90 Nη2 αD GLN1146 Oε1 β3-α3 loop 
  
      
Water-mediated hydrogen 
bonds     
ASP24 Oδ2 
αA-αB 
loop   
SER521 O, Oγ α1 
HIS64 O αC ASP1095 Oδ2 β1-α1 loop 
  
GLY68 O αC ASN1099 Nδ2 α1 
  
      
Salt bridges 
     
ASP24 Oδ2 
αA-αB 
loop   
ARG524 Nη1 α1 
ASP23 Oδ2 
αA-αB 
loop 
 
 LYS525 Nζ α1 
HIS64 Nε2 αC 
ASP1095 Oδ1, 
ASP1144 Oδ2 
β1-α1 loop, β3 
  
 
Experimental data show that Ypd1 has ~1000-fold higher affinity for Ssk1-R2 
than Sln1-R1.  While the apo complexes of Ssk1-R2W638A/Ypd1 and Sln1-R1/Ypd1 
share approximately the same number of hydrophobic contacts, the Sln1-R1/Ypd1 
complex possesses several structural features that are often associated with higher 
binding affinity9-11.  The Ssk1-R2W638A/Ypd1 complex contains only half of the number 
of observed hydrogen bonds, and the Sln1-R1/Ypd1 interface is ~20% larger than the 
Ssk1-R2W638A/Ypd1 interface (analyzed with PDBePISA12).  Because of these 
seemingly contradictory data, additional factors must exist that overwhelmingly 
contribute to the 1000-fold higher binding affinity and complex formation between 
Ssk1-R2 and Ypd1. 
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Other characteristics of the Ssk1-R2W638A/Ypd1 interface can help explain the 
dissimilar biochemical activities observed between Ypd1 and its upstream and 
downstream cognate receiver domains.  The Sln1-R1/Ypd1 structure has a surface 
complementarity score (Sc) of 0.624, and the Ssk1-R2W638A/Ypd1 structure has Sc = 
0.651 (where 0 = no complementarity and 1= perfect complementarity)13.  This 
indicates that as Ypd1 encounters Ssk1-R2W638A, their shapes conform to one another to 
a higher degree than Ypd1/Sln1-R1.  The slightly higher surface complementarity could 
partially contribute to the higher Ypd1/Ssk1-R2 affinity14 and stabilization of Ssk1-
R2~P by Ypd1.   
Although surface complementarity could be a contributing factor, the co-crystal 
structure revealed that the most likely reason for the observed ~25 nM affinity and 
strong transient complex formation between Ypd1 and Ssk1-R2 is electrostatic 
complementarity.  Firstly, the overall electrostatic potential profiles of Sln1-R1 and 
Ssk1-R2W638A are very dissimilar; secondly, the Ssk1-R2W638A/Ypd1 complex revealed a 
unique, contiguous salt bridge patch between the αA-αB loop of Ypd1 and the α1 helix 
of Ssk1-R2W638A. 
The calculated isoelectric point of Ypd1 is ~4, which would cause its overall 
charge to be negative at physiological pH (7.4).  The calculated isoelectric point of 
Sln1-R1 is ~7, suggesting that its overall charge would be neutral at physiological pH.  
The calculated isoelectric point of Ssk1-R2 is ~10.5, indicating that it would carry a 
strong positive charge at physiological pH, causing a heightened attraction between 
Ypd1 and Ssk1-R2.  This overall attraction between Ypd1 and Ssk1-R2 would influence 
kinetic on rates that contribute to affinity15.  Electrostatic potential maps (Figure 40) of 
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the co-crystal structures confirm that large patches of negative potential on Ypd1 
correlate to patches of positive potential on Ssk1-R2W638A.  Similar areas of positive and 
negative potential exist at the Sln1-R1/Ypd1 interface, but are much weaker.  The 
strongest complementary potential occurs at the location of the salt bridge formations 
between Ssk1-R2W638A and Ypd1 (R524-D24 and K525-D23). 
 
Figure 40.  Electrostatic molecular surface representation of the interface view of 
Sln1-R1 and Ssk1-R2W638A with Ypd1.   
Complexes have been pulled apart and rotated 90° in order to directly view interfaces.  A) Ssk1-R2W638A 
(left) and Ypd1 (right).  B) Sln1-R1 (left) and Ypd1 (right) (PDB ID: 1OXB).  Electrostatic maps using 
AMBER ff99 force field16 are shown.  Red represents negative potential, blue represents positive 
potential, and white represents neutral areas.   
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Analysis of Ssk1-R2W638A/Ypd1 and Sln1-R1/Ypd1 active sites 
Comparison of the distances between the phospho-donor and acceptor atoms in 
the active sites of the Sln1-R1/Ypd1 and Ssk1-R2W638A/Ypd1 structures reveals 
differences.  In both apo (4.6 Å; Figure 41, panel A) and BeF3
--activated (4.9 Å; Figure 
41, panel B) structures of Sln1-R1/Ypd1, the distance between the phospho-donor 
(D554 Oδ1) and phospho-acceptor (H64 Nε) is ≤4.9 Å, while the distance between 
phospho-donor and acceptor in apo Ssk1-R2W638A/Ypd1 is 6.3 Å (Figure 41, panel C).   
 
Figure 41.  Distances from Ypd1-H64 to the phosphorylatable aspartate.   
A)  Distance of H64 Nε to D1144 Oδ1 on BeF3--activated Sln1-R1/Ypd1 structure (PDB ID: 2R25).  
Mg2+ shown as a magenta sphere, BeF3- removed for simplicity.  B)  Distance of H64 Nε to D1144 Oδ1 
on apo Sln1-R1/Ypd1 structure (PDB ID: 1OXB).  C)  Distance of H64 Nε to D554 Oδ1 on apo Ssk1-
R2W638A/Ypd1 structure. 
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Since this co-crystal structure likely represents the pre-ground state encounter 
complex of Ssk1-R2W638A/Ypd1, the active site geometry will likely shift upon Mg2+-
binding and phosphorylation as seen in the BeF3
--activated structure of Sln1-R1/Ypd117. 
The anomalous behavior of Ssk1-R2-W638A, Q556A and S612A may hold 
clues to the unique intermolecular interactions of Ssk1-R2 and Ypd1.  Point mutations 
Ssk1-R2-W638A and Q556A transformed a large amino acid to a smaller amino acid, 
possibly allowing the phospho-donor and acceptor to come into closer proximity.  This 
closer proximity could account for the D  H back-transfer reaction observed.  Upon 
encounter, WT Ypd1-H64 and Ssk1-R2-D554 would be under ideal conditions to 
support the favored H  D phosphoryl transfer, due to the high chemical lability of the 
H~P bond18 and the catalytically active receiver domain with a strong aspartate 
nucleophile.  In the WT interaction, a larger distance between the active site residues 
could prevent the reverse reaction from occurring in the Ssk1-R2/Ypd1 complex.  If, 
however, the phospho-donor and acceptor came into closer proximity, the reverse D  
H reaction could occur (observed in Sln1-R1  Ypd11).  Unlike the rapid dissociation 
of Sln1-R1 and Ypd1, which leaves 97% of Ypd1 phosphorylated before the reverse 
reaction can occur1, the higher affinity between Ssk1-R2 and Ypd1 keeps them bound in 
a strong transient complex.  By remaining bound, this could allow back-transfer to 
occur and be observed in phosphotransfer assays.   
In the crystal structure, the position of amino acid 638 of Ssk1 does not come 
into direct contact with Ypd1.  However, the tryptophan could make intramolecular 
contacts with the β5-α5 loop that interfaces with Ypd1, changing the docking position 
of WT Ssk1-R2 and maintaining a larger distance between the phospho-donor and 
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acceptor in the active site.  Position 556 of Ssk1-R2 is directly in the active site in this 
co-crystal structure.  The glutamine side chain has a very high B-factor (50.3 Å2), 
indicating the ability to adopt multiple conformations, which was not observed in either 
the apo or BeF3
--activated Sln1-R1/Ypd1 complexes17, 19.  The highly flexible Q556 in 
the apo structure could be stabilized in the phosphorylated structure, keeping a larger 
distance between the phospho-donor and acceptor atoms in the active site.  Both of 
these residues could also be involved in keeping the active site closed off and shielded 
from a hydrolytic water, accounting for the WT Ssk1-R2~P/Ypd1 stabilization. 
Ssk1-W638A~P and Q556A~P were both observed to have a 3-fold increase in 
phosphorylated half-lives in the presence of Ypd1-H64Q 3-fold over WT.  Extended 
half-life experiments were repeated with WT proteins on the newer phosphorimaging 
equipment and slight discrepancies did not appear on the hour timescale like they did on 
the minute timescale.  As seen in Janiak-Spens et al.3, glutamine is a poor substitute for 
histidine when stabilizing WT Ssk1-R2~P (~40 hours with WT Ypd1 vs. ~2 hours with 
Ypd1-H64Q).  If W638 and Q556 are involved in maintaining the >6 Å distance 
between Ypd1-H64 and Ssk1-R2-D554~P, mutating them to alanine could bring the 
phosphoryl group closer to the nitrogen on Ypd1-H64Q, creating a shorter, stronger 
hydrogen bond, explaining the observed 3-fold increase of the phosphorylated half-lives 
of Ssk1-R2-W638A~P and Q556A~P. 
Mutant Ssk1-R2-S612A~P did not exhibit normal autodephosphorylation 
activity in phosphotransfer assays (WT t½ is on a ~13-23 min timescale).  T610 is 
known to “switch” orientation upon phosphorylation to help stabilize the activated RR 
structure.  Residue S612 is positioned in a way to be able to interact with T610, but the 
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current co-crystal structure does not yield enough information to form a working 
hypothesis about this mechanism of the apparent stabilization of Ssk1-R2-S612A~P.  In 
order to gain more insight, a BeF3
--activated WT co-crystal structure of Ssk1-R2 and 
Ypd1 would be very informative. 
Discussion 
In conclusion, a point mutant of Ssk1-R2 was discovered that yielded great 
solubility benefits and allowed for the co-crystallization of Ssk1-R2W638ASeMet with 
Ypd1.  The co-crystal structure showed conservation of the (βα)5 topology of receiver 
domains, confirmed the shared Ypd1/RR hydrophobic docking site, and also 
highlighted differences at the Ypd1/RR interfaces.  The insertion of a single polar 
residue in the hydrophobic docking site abolished Ssk1-R2/Ypd1 binding and greatly 
diminish phosphotransfer ability.   
Point mutations of intermolecular salt bridge residues (Ssk1-R2-R524A and 
K525A) showed that these ionic interactions played an important role in Ssk1-R2/Ypd1 
affinity, but did not abolish Ypd1 phosphotransfer activity.  Electrostatic potentials of 
Ypd1, Sln1-R1 and Ssk1-R2 could also explain to the ~1000-fold increase in affinity 
observed between Ypd1 and Ssk1-R2 over Sln1-R1. Ssk1 and Ypd1 should form a 
strong transient complex in vivo, explaining the constitutively phosphorylated state of 
Ssk1 under non-stress conditions.  If electrostatic interactions are the primary basis for 
the Ypd1/Ssk1 complex formation, this would corroborate the reduced phospho-
stability of Ssk1-R2~P by Ypd1 in response to osmolyte concentration20.  The initial 
cellular response to hyperosmotic stress is a rapid efflux of water out of the cell, 
creating a slightly higher intracellular salt concentration.  This could function as a 
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physiological “switch” to promote dissociation of the Ssk1-R2/Ypd1 complex in vivo, 
activating the HOG1 pathway.  High levels of intracellular glycerol would again favor 
Ssk1-R2/Ypd1 complex formation.  This could provide clues for the physiological role 
for Ypd1 and Ssk1 in the Sln1 pathway in response to hyperosmotic stress. 
Residues W638 and Q556 were found to play a role in the apparent 
irreversibility of the Ypd1  Ssk1-R2 phosphotransfer reaction, and I hypothesize that 
these residues are involved in maintaining a >6 Å distance between Ypd1-H64 and 
Ssk1-R2-D554, as well as shielding Ssk1-R2-D554~P from hydrolytic water when in 
complex.  Point mutant S612A did not show WT autodephosphorylation activity, but 
any explanation would be highly speculative with the current data. 
Studying the nature of protein-protein interactions in the Sln1 signaling pathway 
has answered some questions but also raised others.  The process of how 
unphosphorylated Ssk1 dissociates from Ypd1 and binds Ssk2 has not been elucidated.  
Previous studies suggest that Ssk1 acts as an unphosphorylated dimer in the cell to bind 
to Ssk2/227, but the dimerization interface has not yet been described.  Comparing the 
following in vitro affinities could shed light on the Ypd1/Ssk1~P in vivo dissociation, 
Ssk1 dimerization and Ssk1/Ssk2 binding event: Ypd1/Ssk1-R2 vs. Ssk1-R2~P, Ssk1-
R2 /Ssk1-R2~P vs.Ssk1-R2.  In addition, we have no structural information on full-
length Ssk1.  Both BLAST searches and homology modeling have turned up no clues as 
to the function of the N-terminal domain of S. cerevisiae Ssk1.  Structural analysis of 
full-length S. cerevisiae Ssk1 would greatly help elucidate the complete function of 
Ssk1 in the Sln1 pathway. 
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Chapter 5: Plasmid expression constructs for Ssk1 from Cryptococcus 
neoformans 
Introduction 
Cryptococcus neoformans is currently one of the most deadly of all human 
fungal pathogens1.  Infections occur mostly in immunocompromised people and cause 
over 600,000 deaths annually worldwide2.  C. neoformans is the most lethal 
opportunistic infection of AIDS patients in Africa (survival rate <40%) and continues to 
be a problem even in regions where current antifungal treatments are available.  A one 
year mortality study was performed in Bangkok, Thailand, on AIDS patients infected 
with cryptococcosis.  Even with treatment of amphotericin B, flucytosine, fluconazole 
and intraconazole, patient mortality rate was greater than 40 %3.  Individuals with 
competent immune systems are generally equipped to handle exposure to fungal 
pathogens, but recently a related species, Cryptococcus gattii was found to be infectious 
to healthy people4.  These developments have led to an increased urgency for the 
development of new antifungal therapies. 
Cryptococcus is a basidiomycete yeast found in pigeon excrement, trees and 
soil.  First exposure is usually through inhalation into the respiratory tract and normally 
initiates immediate immune responses such as phagocytosis and proinflammatory 
reactions.  C. neoformans has adapted to invade the immunocompromised host via 
known virulence factors: polysaccharide capsule, melanin, cell enlargement, and sexual 
reproduction (α mating type). The Cryptococcus polysaccharide capsule blocks 
recognition by host phagocyte-expressed pattern-recognition receptors, while melanin 
prevents oxidative damage and promotes survival inside phagocytes.  Melanin also 
allows cells to resist temperature, heavy metal and ionizing radiation stress4, 5. 
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During its sexual cycle, C. neoformans switches from unicellular budding yeast 
to hyphal growth.  Spores produced during mating are infectious and can colonize lung 
tissue, propagate in the blood, and cross the blood-brain barrier, ultimately colonizing 
brain tissue.  Mating can also produce clinically relevant hybrids, although the yeast 
form is the most common morphological form in host infections6. 
To combat deadly fungal pathogens, new drugs are urgently needed.  Current 
therapies are often toxic, lack efficacy or are rendered less effective due to the 
emergence of antifungal resistant strains.  With the exception of 5-flucytosine, all 
current antifungals targeting systemic infection target cellular integrity.  This is 
problematic since fungal pathogens are eukaryotes and share many similarities in 
proteins and cellular structure with humans.  Only two known compounds are in the 
antifungal pipeline that have novel targets, and no new antifungal medications have 
been approved since 2006.  As of 2015, at most 6 new compounds are in active clinical 
development for systemic fungal infections1.  Cryptococcus species are intrinsically 
resistant to echinocandins (targets β-Glucan synthesis) and cryptococcal meningitis 
responds poorly to fluconazole (targets ergosterol biosynthesis)1.  These characteristics 
make C. neoformans an excellent candidate for studying novel antifungal drug targets. 
An ideal drug target would be essential to survival or virulence in the pathogen 
and be absent in the host organism.  TCS proteins have been implicated in virulence in 
multiple pathogenic species (reviewed in Shor et al.7).  No TCS inhibitor has yet 
reached clinical stages, even though inhibitor identification efforts have been going on 
for approximately 20 years.  Most have focused on the inhibition of HK 
phosphorylation, not downstream HPts or RRs7.  The TCS pathway that is upstream of 
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the C. neoformans HOG1 stress response pathway has been identified as an excellent 
candidate and may contain viable drug targets.  The C. neoformans Tco pathway is 
homologous to the model organism S. cerevisiae Sln1 pathway.   
The C. neoformans Tco system controls the HOG1 pathway, regulates stress 
responses, antifungal sensitivity, virulence factors and sexual reproduction (Figure 42 
(pg. 92)).  Histidine kinases Tco 1-7 don’t contain transmembrane domains, so they are 
likely cytosolic8.  Some Tco proteins interact with Ypd1 which functions as an 
intermediate HPt protein in the pathway.  It interacts with Ssk1 and is also essential for 
C. neoformans survival.  The fact that there is no Ypd1 homolog in mammals and that it 
is essential for survival make it a highly desirable drug target.  All information about 
CnYpd1 and its cognate partners would be of great clinical interest.   
C. neoformans Hog1 phosphorylation requires Ssk1. Ssk1 is essential in 
response to oxidative stress or UV irradiation.  It is important but not essential in 
mediating osmotic stress responses.  Deletion of Ssk1 increases fludioxonil and high 
temperature resistance.  Ssk1 negatively regulates sexual reproduction.  Disruption of 
the Ssk1 gene dramatically enhanced capsule and melanin productions, indicating that 
the HOG1 pathway negatively regulates virulence8.   
Cryptococcus hyper-virulent serotype A H99 (>95% of clinical isolates 
worldwide) has opposite HOG1 regulation than the less virulent Cryptococcus serotype 
D JEC21 strains and other yeasts.  The HOG1 pathway is uniquely suited to attenuate 
virulence and differentiation in H99 but not JEC21 even though they share ~95% 
genome sequence identity.  CnHOG1 is a true functional homolog of ScHOG1 because 
it rescued a Schog1Δ strain from hyper-osmosensitivity. Crosstalk is present between 
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HOG1 pathway and cAMP signaling pathway, which controls biosynthesis of capsule 
and melanin.  Normally, Hog1 is unphosphorylated and is quickly phosphorylated and 
activated in response to hyperosmotic stress.  Serotype D (JEC21) and S. cerevisiae 
both have this pattern. Serotype A (H99) has the opposite regulation; Hog1 is 
constitutively phosphorylated and is rapidly dephosphorylated upon exposure to 1M 
NaCl.  Hog1 in serotype A and D can complement each other- the difference is in the 
upstream or downstream proteins.  In serotype D and S. cerevisiae, Hog1 localizes to 
the nucleus after osmotic stress, but in serotype A, Hog1 is more evenly distributed 
between cytosol and nucleus.  Hog1 is phosphorylated by Pbs2 as in the S. cerevisiae 
pathway9.  Ssk2 is the likely upstream factor that distinguishes between constitutive 
Hog1 phosphorylation or dephosphorylation by interacting with Pbs210.  There are two 
informative reviews on the current understanding of the Cryptococcus Hog1 pathway11, 
12. 
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Figure 42.  Illustration of HOG1 pathway in C. neoformans. 
Figure adapted from12. 
 
In C. neoformans H99, Ssk1 is the link between Ypd1 (putative drug target, 
essential for survival) and Ssk2, the “master switch” for controlling the hyper-virulent 
characteristic of constitutive Hog1 phosphorylation.  Although the S. cerevisiae Sln1 
pathway is an important model system, there are many differences that support the 
rationale to study C. neoformans signaling proteins directly.  Sequence alignments of S. 
cerevisiae Ssk1 and C. neoformans Ssk1 show high conservation of the receiver 
domains region but little overall similarity.  Full length Ssk1 proteins share 17.1% 
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identity (global alignment with EBLOSUM62 matrix, Emboss Needle13) but a pairwise 
alignment illustrates that 189 residues encompassing the receiver domains share 51.9% 
identity (BLOSUM62 matrix, Expasy SIM14).  These residues are 987-1175 of CnSsk1 
and 483-666 of ScSsk1.  High conservation of the receiver domain is shown in Figure 
43. 
 
Figure 43.  Sequence alignment of Sc and Cn Ssk1 receiver domains.   
This figure was generated by JalView15 using the Clustal algorithm16. 
 
In this chapter, attempts were made to purify portions of CnSsk1 for structural 
and biochemical characterization. 
CnSsk1 homology modeling 
Full length CnSsk1 was submitted to homology modeling using the Phyre2 
program17.  From the tertiary structure predictions, three discreet domains were 
generated.  In order to investigate their putative functions, each domain was submitted 
separately to an amino acid sequence BLAST search18.  Domain 1 (aa 265-425) and 
domain 2 (aa 650-825) returned no similarities to known domains.  When submitted to 
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3D BLAST19 and compared to known structures in the Protein Data Bank (PDB)20 
(http://www.rcsb.org/pdb/), both domains returned almost identical structure similarity 
to the catalytic subunit of a histidine kinase.  Domain 1 was most similar to a 
Thermatoga maritima histidine kinase (PDB ID: 2C2A) with rmsd = 0.77 Å and 
sequence identity = 12.1%.  Domain 2 was most similar to T. maritima histidine kinase 
CheA (PDB ID: 2CH4) with rmsd = 1.10 Å and sequence identity = 5.1%.  Domain 3 
(aa 1005-1165) was identified as an RR receiver domain (referred to as CnR2) by 
sequence identity and structural similarity (Figure 44).  Domain 1 amino acid sequence 
was submitted separately to Phyre2 and the top model was returned with 97% 
confidence and 44% coverage as an ATPase domain of HSP90 chaperone/DNA 
topoisomerase II/histidine kinase fold from the histidine kinase family.  When domain 2 
was submitted for homology modeling alone, the predicted structure was not similar to 
a histidine kinase (it was mostly disordered).  In conclusion, domain 1 may be a 
histidine kinase domain, but domain 2 is ambiguous.   
 
Figure 44.  Homology models of 3 putative domains of CnSsk1.   
A)  CnSsk1 domain 1 (aa 265-425, magenta) superpositioned with a sensor histidine kinase from T. 
maritima (PDB ID: 2C2A, cyan).  B)  CnSsk1 domain 2 (aa 650-825, magenta) superpositioned with 
CheA from T. maritima (PDB ID: 2CH4, cyan).  C) CnSsk1 domain 3 (CnR2, aa 1005-1165) receiver 
domain exhibiting the canonical (βα)5 fold. 
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In order to generate working plasmid expression constructs, segments were 
PCR-amplified from C. neoformans H99 cDNA and inserted into expression vectors to 
create fusion proteins.  Sequencing of the cDNA revealed that we did not have full 
coverage of the CnSsk1 gene, making the creation of a full-length CnSsk1 protein 
impossible.  Experiments to collect cDNA from CnSsk1 were done in the lab of Dr. Jan 
Fassler at the University of Iowa before I joined the West lab, and it was impractical to 
obtain the missing nucleotides.  We had coverage from nucleotide 1-1210 (amino acid 
1-403) and nucleotide 1057-3930 (amino acid 650 through the C-terminal end).   
Therefore we decided to mainly focus on purification of the receiver domain (CnR2), ± 
domain 2 or ± the C-terminal tail in order to evaluate protein-protein interactions with 
CnYpd1.  Twelve constructs were created (named CnR2-B – CnR2-M) (Figure 45 (pg. 
96)) to evaluate expression, solubility and phosphotransfer activity.  In general, these 
protein constructs were difficult to work with.  Many were insoluble.  The protein 
constructs that were soluble were difficult to purify, and once purification was 
complete, phosphotransfer activity with CnYpd1 was not observed.  The following is a 
summary of the work that was accomplished in pursuit of knowledge about the Tco1 
His-Asp phosphorelay pathway of the human pathogen C. neoformans.   
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Figure 45.  Schematic representation of all fusion proteins created from CnSsk1. 
 
CnR2-A 
CnR2-A (~26 kDa) was a His-tagged construct created by Lu Zhou.  This 
construct was purified and crystallized but it was discovered that the final purified 
protein was not CnR2.  Another 26 kDa protein was overexpressed by the addition of 
IPTG and was purified by a combination of Ni-NTA affinity and ion exchange 
chromatography.   From mass spectrometry peptide ID, it was identified as beta-
lactamase, the ampicillin-resistance gene carried on the pET16b plasmid. 
CnR2-B 
The construct, CnR2-B was created from cDNA nucleotides 2989-3912 of the 
C. neoformans H99 Ssk1 gene (Figure 46 (pg. 97)).  The final 341 amino acid fusion 
protein had a C-terminal 6x His-tag, a calculated molecular mass of 37,239 Da and a 
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theoretical isoelectric point of 9.51.  CnR2-B was not expressed in Rosetta cells (Figure 
47). 
 
 
Figure 46.  Plasmid map of construct CnR2-B. 
 
Figure 47.  SDS-PAGE gel showing the absence of fusion protein CnR2-B.   
M- protein marker, 1- uninduced Rosetta cells + empty vector, 2- induced Rosetta cells + empty vector, 
3- uninduced Rosetta cells + vector with CnR2-B insert, 4- induced Rosetta cells + vector with CnR2-B 
insert.  CnR2-B (~37 kDa). 
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CnR2-C 
The construct, CnR2-C was created from cDNA nucleotides 3001-3525 of the 
C. neoformans H99 Ssk1 gene (Figure 48 (pg. 99)).  The final 693 amino acid fusion 
protein had a C-terminal intein-chitin binding domain (CBD) tag, a calculated 
molecular mass of 76,966 Da and a theoretical isoelectric point of 8.55.  After cleavage 
of the intein tag (Figure 49 (pg. 99)), the final 176 amino acid protein had a calculated 
molecular mass of 19,448 Da and a theoretical isoelectric point of 8.97.  CnR2-C was 
confirmed with mass spectrometry peptide ID as a portion of C. neoformans Ssk1. 
Chitin affinity chromatography was successful as the first step of purification in CnR2-
C.  However, after concentration and size-exclusion chromatography, most of the 
protein became insoluble.  Cation exchange was also attempted as a second purification 
step but the results were identical.  Protein yield was undetectable after each second 
purification step.  CnR2-C was, therefore, not used in any activity assays. 
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Figure 48.  Plasmid map of construct CnR2-C. 
 
Figure 49.  SDS-PAGE gels showing fusion protein CnR2-C.   
A)  M- protein marker, 1- uninduced Rosetta cells, 2- induced Rosetta cells overexpressing CnR2-C (~77 
kDa).  B)  1- pellet of cleaved CnR2-C, M- protein marker, 2- supernatant of cleaved CnR2-C.  After 
cleavage of the intein-CBD tag (~19 kDa) and concentration, the majority of CnR2-C was insoluble. 
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CnR2-D 
The construct, CnR2-D was created from cDNA nucleotides 3001-3927 of the 
C. neoformans H99 Ssk1 gene (Figure 50 (pg. 101)).  The final 827 amino acid fusion 
protein had a C-terminal intein-chitin binding domain tag, a calculated molecular mass 
of 91,236 Da and a theoretical isoelectric point of 8.76.  After cleavage of the intein tag, 
the final 310 amino acid protein had a calculated molecular mass of 33,717 Da and a 
theoretical isoelectric point of 9.32.  CnR2-D was confirmed with mass spectrometry 
peptide ID as a portion of C. neoformans Ssk1.  CnR2-D was successfully purified by 
chitin affinity chromatography as a first step.  Size exclusion, cation exchange and 
phenyl sepharose chromatography were all attempted as a final step.  Phenyl sepharose 
and cation exchange were unsuccessful because they did not separate CnR2-D from 
other proteins.  Size exclusion was not successful because CnR2-D became partially 
insoluble during the concentration step before chromatography and the remaining 
soluble protein was not separated from higher molecular weight proteins (Figure 51 (pg. 
101)).   Despite the remaining impurities, CnR2-D was subjected to a phosphotransfer 
assay with CnYpd1 but did not display any activity (data not shown). 
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Figure 50.  Plasmid map of construct CnR2-D. 
 
Figure 51.  SDS-PAGE gels showing fusion protein CnR2-D.   
A)  M- protein marker, 1- uninduced Rosetta cells, 2- induced Rosetta cells overexpressing CnR2-D (~91 
kDa).  B)  M- protein parker, 1- CnR2-D after cleavage of intein-CBD tag (~34 kDa).  C)  M- marker, 1-
7- fractions 30-37 of a gravity S-100 size exclusion column.  Gel illustrates that the majority of CnR2-D 
elutes with higher molecular weight proteins and the remaining pure protein was negligible. 
 
102 
CnR2-E 
The construct, CnR2-E was created from cDNA nucleotides 3001-3927 of the C. 
neoformans H99 Ssk1 gene (Figure 52 (pg. 103)).  The final 331 amino acid fusion 
protein had an N-terminal 10x His-tag, a calculated molecular mass of 36,238 Da and a 
theoretical isoelectric point of 9.32.  CnR2-E was confirmed with mass spectrometry 
peptide ID as a portion of C. neoformans Ssk1.  During Ni-NTA affinity 
chromatography, a portion of the protein appeared in the FT and did not appear to bind 
completely.  Even though it did not bind completely, the protein yield at early stages 
was much more promising than constructs C-D.  Cobalt and nickel HP Chelating 
columns (GE Healthcare) run on an AKTA prime chromatography system with 
imidazole gradients were attempted; nickel had the fewest impurities in the fractions 
containing CnR2-E.  Unfortunately, cobalt and nickel affinity columns did not enrich 
CnR2-E.  The protein was spread through approximately 15-20 fractions with no “peak” 
(Figure 53 (pg. 103)).  During the concentration step before size exclusion 
chromatography, a significant amount of the protein was observed to be insoluble.  In 
order to try to improve solubility and yield, an alanine substitution was introduced to 
W1147, the tryptophan residue that aligns with W638 in S. cerevisiae Ssk1-R2.  
Expression and purification attempts of CnR2-E-W1147A were identical to CnR2-E 
(Figure 54 (pg. 104)).  A non-phosphorylatable mutant (CnR2-E-D1058A) was created, 
but was never purified or used in activity assays.  After construct CnR2-E showed some 
promise, constructs F-M were created to capitalize on the success of the His-tag while 
searching for a protein composition that would be more amenable to purification and 
crystallization.   
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Figure 52.  Plasmid map of construct CnR2-E. 
 
Figure 53.  SDS-PAGE gels showing fusion protein CnR2-E.   
A)  M- protein marker, 1- uninduced Rosetta cells, 2- induced Rosetta cells overexpressing CnR2-E (~36 
kDa).  B)  M- protein marker, 1- supernatant after Ni-NTA chromatography and concentration, 2- pellet 
after Ni-NTA chromatography and concentration.  Approximately 50% of CnR2-E is soluble. C)  1-9- 
fractions 36-44 of HP Chelating Ni-NTA column (GE Healthcare), M- marker.  Gel illustrates that CnR2-
E is not enriched by chromatography, but was spread over many fractions. 
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Figure 54.  SDS-PAGE gels showing fusion protein CnR2-E-W1147A.   
A)  M- protein marker, 1- uninduced Rosetta cells, 2- induced Rosetta cells overexpressing CnR2-E-
W1147A (~36 kDa), 3- supernatant of whole cell lysate, 4- pellet of whole cell lysate.  The majority of 
CnR2-E-W1147A is soluble before purification.  C)  1-9- fractions 54-62 of a HP Chelating Ni-NTA 
column (GE Healthcare), M- marker.  Gel illustrates that CnR2-E-W1147A was not enriched by 
chromatography, but was spread over many fractions 
 
CnR2-F 
The construct, CnR2-F, was created from cDNA nucleotides 3022-3930 of the 
C. neoformans H99 Ssk1 gene (Figure 55 (pg. 105)).  The final 324 amino acid fusion 
protein had an N-terminal 10x His-tag, a calculated molecular mass of 35,532 Da and a 
theoretical isoelectric point of 9.43.  CnR2-F was expressed in Rosetta cells at 37 °C 
(Figure 56, panel A (pg. 105)), ambient temperature (24-30 °C) and 16 °C.  The protein 
was approximately 50% soluble at 37 °C, but improved to 75% solubility at ambient 
temperature and 16 °C.  CnR2-F eluted with 600 mM imidazole from a hand-poured Ni-
NTA column, and remained soluble after dialysis into a low-salt buffer.  CnR2-F eluted 
from a Hi-Trap Ni-NTA (GE Healthcare) 5 mL column using the AKTA prime system, 
but the protein was spread through many fractions (Figure 56, panel B(pg. 105)).  After 
concentrating and freezing the protein at -20  °C in 50 mM Tris pH 8.0, 100 mM KCl, 
15 mM MgCl2 and 10% glycerol, CnR2-F showed precipitation when thawed on ice.  
105 
Although relatively pure, the yield was low (0.32 mg/L).  CnR2-F was not subjected to 
further purification attempts. 
 
Figure 55.  Plasmid map of construct CnR2-F. 
 
 
Figure 56.  SDS-PAGE gels showing fusion protein CnR2-F.   
A)  M- marker, 1- uninduced Rosetta cells, 2- induced Rosetta cells overexpressing CnR2-F (~36 kDa).  
B)  1-9- fractions 36-44 of a HP Chelating Ni-NTA column (GE Healthcare), M- marker.  Gel illustrates 
that CnR2-F was not enriched by chromatography, but was spread over many fractions. 
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CnR2-G 
The construct, CnR2-G was created from cDNA nucleotides 1948-3927 of the 
C. neoformans H99 Ssk1 gene (Figure 57).  The final 682 amino acid fusion protein had 
an N-terminal 10x His-tag, a calculated molecular mass of 74,127 Da and a theoretical 
isoelectric point of 9.89.  CnR2-G was expressed in Rosetta cells at 37 °C, ambient 
temperature (24-30 °C) and 16 °C.  The protein was mostly insoluble at 37 °C, but had 
improved solubility at ambient temperature and 16 °C.  Protein expression in all 
temperatures was very low.  Upon scale-up, CnR2-G did not bind Ni-NTA resin during 
chromatography (Figure 58 (pg. 107)).  CnR2-G was not subjected to further 
purification attempts. 
 
Figure 57.  Plasmid map of construct CnR2-G. 
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Figure 58.  SDS-PAGE gel showing Ni-NTA purification attempt of CnR2-G.   
M- protein marker, 1- uninduced Rosetta cells, 2- whole cell lysate of Rosetta cells at 16 °C showing the 
overexpression of CnR2-G (~74 kDa), 3- supernatant, 4- pellet, 5- flow-thru showing the presence of 
CnR2-G, 6- flow-thru showing the presence of CnR2-G, 7- 100 mM imidazole wash 1, 8- 100 mM 
imidazole wash 2, 9- 200 mM imidazole wash.   
 
CnR2-H 
The construct, CnR2-H was created from cDNA nucleotides 1948-3780 of the 
C. neoformans H99 Ssk1 gene (Figure 59 (pg. 108)).  The final 633 amino acid fusion 
protein had an N-terminal 10x His-tag, a calculated molecular mass of 68,810 Da and a 
theoretical isoelectric point of 10.11.  Due to its similarity to CnR2-G and CnR2-I, 
expression studies were not done on CnR2-H. 
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Figure 59.  Plasmid map of construct CnR2-H. 
 
CnR2-I 
The construct, CnR2-I was created from cDNA nucleotides 1948-3573 of the C. 
neoformans H99 Ssk1 gene (Figure 60 (pg. 109)).  The final 564 amino acid fusion 
protein had an N-terminal 10x His-tag, a calculated molecular mass of 61,571 Da and a 
theoretical isoelectric point of 9.94. CnR2-I was expressed in Rosetta cells at 37 °C and 
16 °C.  The protein was completely insoluble at 16 °C (Figure 61 (pg. 109)).  CnR2-I 
was not subjected to further purification attempts. 
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Figure 60.  Plasmid map of construct CnR2-I. 
 
Figure 61.  SDS-PAGE gel showing fusion protein CnR2-I.   
1- uninduced Rosetta cells, 2- induced Rosetta cells overexpressing CnR2-I (~62 kDa), 3- supernatant of 
whole cell lysate at 16 °C, 4- pellet of whole cell lysate at 16 °C, M- protein marker.  CnR2-I was 
insoluble.   
 
CnR2-J 
The construct, CnR2-J was created from cDNA nucleotides 3022-3780 of the C. 
neoformans H99 Ssk1 gene (Figure 62 (pg. 110)).  The final 262 amino acid fusion 
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protein had a C-terminal 6x His-tag, a calculated molecular mass of 28,759 Da and a 
theoretical isoelectric point of 9.82.  CnR2-J was overexpressed in Rosetta cells at 37 
°C (Figure 63, panel A (pg. 111)), ambient temperature and 16 °C.  Solubility was 
greatest at 16 °C, so a scale-up culture was grown and purified by nickel and cobalt 
affinity chromatography.  Nickel gave better separation, although the protein was not 
enriched by chromatography; it was spread out over approximately 20 fractions.  
Despite this, the fractions were pooled, concentrated and subjected to size-exclusion 
chromatography which did not further purify the sample (Figure 63, panel B (pg. 111)).  
Despite the remaining impurities, CnR2-J was subjected to a phosphotransfer assay with 
CnYpd1 but did not display any activity. 
 
Figure 62.  Plasmid map of construct CnR2-J. 
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Figure 63.  SDS-PAGE gels showing fusion protein CnR2-J.   
A)  M- marker, 1- uninduced Rosetta cells, 2- induced Rosetta cells overexpressing CnR2-J (~29 kDa).  
B)  1- size exclusion chromatography load, M- protein marker, 2-7- fractions 18-23 of size exclusion 
chromatography column.  Gel illustrates that CnR2-J is not significantly purified by size exclusion 
chromatography after Ni-NTA affinity chromatography. 
 
CnR2-K 
The construct, CnR2-K was created from cDNA nucleotides 3022-3573 of the 
C. neoformans H99 Ssk1 gene (Figure 64 (pg. 112)).  The final 193 amino acid fusion 
protein had a C-terminal 6x His-tag, a calculated molecular mass of 21,521 Da and a 
theoretical isoelectric point of 9.17. CnR2-K was expressed in Rosetta cells at 37 °C 
(Figure 65 (pg. 112)), ambient temperature, and 16 °C.  The majority of the protein was 
insoluble at all temperatures. 
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Figure 64.  Plasmid map of construct CnR2-K. 
 
Figure 65.  SDS-PAGE gel showing fusion protein CnR2-K.   
M- marker, 1- induced Rosetta cells overexpressing CnR2-K (~22 kDa), 3- supernatant of whole cell 
lysate, 4- pellet of whole cell lysate.  CnR2-K was insoluble.   
 
CnR2-L 
The construct, CnR2-L was created from cDNA nucleotides 1948-3780 of the C. 
neoformans H99 Ssk1 gene (Figure 66 (pg. 113)).  The final 620 amino acid fusion 
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protein had a C-terminal 6x His-tag, a calculated molecular mass of 67,354 Da and a 
theoretical isoelectric point of 10.07.  CnR2-L was expressed in Rosetta cells at 37 °C 
(Figure 67), ambient temperature, and 16 °C.  The majority of the protein was insoluble 
at all temperatures. 
 
Figure 66.  Plasmid map of construct CnR2-L. 
 
Figure 67.  SDS-PAGE gel showing fusion protein CnR2-L.   
M- marker, 1- induced Rosetta cells overexpressing CnR2-L (~67 kDa), 3- supernatant of whole cell 
lysate at 37 °C, 4- pellet of whole cell lysate at 37 °C.  CnR2-L was equally insoluble at all temperatures.   
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CnR2-M 
The construct, CnR2-M was created from cDNA nucleotides 1948-3573 of the 
C. neoformans H99 Ssk1 gene (Figure 68).  The final 551 amino acid fusion protein had 
a C-terminal 6x His-tag, a calculated molecular mass of 60,116 Da and a theoretical 
isoelectric point of 9.90. CnR2-M was expressed in Rosetta cells at 37 °C and 16 °C.  
The protein was completely insoluble at 16 °C (Figure 69 (pg. 115)).  CnR2-M was not 
subjected to further purification attempts. 
 
Figure 68.  Plasmid map of construct CnR2-M. 
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Figure 69.  SDS-PAGE gel showing fusion protein CnR2-M.   
M- marker, 1- uninduced Rosetta cells, 2- induced Rosetta cells overexpressing CnR2-M (~60 kDa), 3- 
supernatant of whole cell lysate, 4- pellet of whole cell lysate.  CnR2-M was insoluble.   
 
Discussion 
In total, 14 attempts to purify CnR2 to crystallization standards were made.  
Overall, the factors that improved solubility were the presence of the 135-amino acid C-
terminal tail, the presence of a His-tag, phosphate buffer, salt, and the combination of 
glycerol and Triton X-100.  The proteins that made it through multiple purification 
steps, however, were not active in phosphotransfer assays (data not shown).  It is likely 
that the protein’s inactivity was due to insolubility or misfolding and should not be 
interpreted as evidence that CnSsk1 does not receive a phosphoryl group from CnYpd1.  
It could be that CnR2 is inactive but full length CnSsk1 is the active form of the protein.  
It is also possible that using yeast or insect cells to express CnSsk1 constructs would be 
more successful than using E. coli as the expression vector. 
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Experimental Section 
Construction of vectors 
The construction of CnR2-B consisted of PCR amplification of the desired 
nucleotides from C. neoformans cDNA (5a) followed by TOPO cloning directly into an 
expression vector.  The construction of plasmids CnR2 C-M was carried out by PCR 
amplification from C. neoformans cDNA (5a) followed by TOPO-TA cloning into an 
intermediate vector, restriction digest, and ligation into an expression vector (Table 7 –
Table 8). 
Table 7.  C. neoformans Ssk1-R2 construct oligonucleotides used in PCR  
(For more information, see Appendix B) 
Oligo Description 
 
Sequence 
 
AW727 CnR2-B 5' primer 5' CACCATGAAGAATGCTAAAGTCG 3' 
AW728 CnR2-B 3' primer 5' ATAGGTCTTTGAGGGCGTAATG 3' 
AW729 CnR2-C, D, E 5' primer 5' GCGCATATGGTCGATGTTGTGGTGCCGCCC 3' 
AW730 CnR2-C 3' primer 5' CTGCCCGGGGGTATCGGAGCTCTTCCATCG 3' 
AW731 CnR2-D 3' primer 5' ATACCCGGGTGGGGGAGGAGCCGGATAG 3' 
AW783 CnR2-E 3' primer 5' CAAAGGATCCTTATGGGGGAGGAGCCGG 3' 
AW903 CnR2-F, J, K 5' primer 5' GTGGTGCATATGATCAACGTGC 3' 
AW904 CnR2-F, G 3' primer 5' CTTCCGCTCGAGCGGTCATG 3' 
AW905 
CnR2-G, H, I, L, M 5' 
primer 
5' TCCACCCATATGTTGCGACAGG 3' 
AW906 CnR2-H 3' primer 5' GAAGACCTCGAGTCATGTCTTGTTC 3' 
AW907 CnR2-I 3' primer 5' CAAGCGACTCGAGTCACTGTTGAG 3' 
AW908 CnR2-J, L 3'e primer 5' GACATCCTCGAGTGTCTTGTTCAG 3' 
AW909 CnR2-K, M  3' primer 5' CGACCTCTCGAGCTGTTGAGGG 3' 
AW836 
CnR2-E D1058A 5’ 
primer 
5’ CCATCTGATTCTGATGGCTATCCAATTGCCCGTCA 3' 
AW837 
CnR2-E D1058A 3’ 
primer 
5’ TGACGGGCAATTGGATAGCCATCAGAATCAGATGG 3' 
AW869 
CnR2-E W1147A 5’ 
primer 
5’ GACCAAGCCTGTGTCTTTGAAAGCGTTGGACAAAAAGATT 3' 
AW870 
CnR2-E W1147A 3’ 
primer 
5’ AATCTTTTTGTCCAACGCTTTCAAAGACACAGGCTTGGTC 3' 
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Table 8.  PCR and plasmid construction details 
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B Pfx 51 °C no n/a n/a 
pET101/D-
TOPO 
n/a 
C 
platinum 
Taq 
64 °C yes NdeI SmaI pET-CYB2 n/a 
D 
platinum 
Taq 
64 °C yes NdeI SmaI pET-CYB2 n/a 
E 
platinum 
Taq 
64 °C yes NdeI BamHI pET16b 
D1058A, 
W1147A 
F 
Emerald 
Taq 
50 °C yes NdeI XhoI pET16b n/a 
G 
Emerald 
Taq 
50 °C yes NdeI XhoI pET16b n/a 
H 
Emerald 
Taq 
50 °C yes NdeI XhoI pET16b n/a 
I 
Emerald 
Taq 
50 °C yes NdeI XhoI pET16b n/a 
J 
Emerald 
Taq 
50 °C yes NdeI XhoI pET21a n/a 
K 
Emerald 
Taq 
50 °C yes NdeI XhoI pET21a n/a 
L 
Emerald 
Taq 
50 °C yes NdeI XhoI pET21a n/a 
M 
Emerald 
Taq 
50 °C yes NdeI XhoI pET21a n/a 
 
Transformation 
Transformations were carried out by incubating nanogram quantities of plasmid 
DNA with competent E. coli cells (50-250 µL) on ice for 30 minutes followed by a 30-
45 second heat-shock at 42 °C.  After cooling cells on ice for 2-5 minutes, LB or SOC 
was added to the reaction up to 500-1000 µL and cells were incubated for 60 minutes, 
200 rpm, 37 °C.  Cells were plated on LB + antibiotic and incubated over night at 37 
°C.   
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Expression and solubility 
All constructs were initially tested for expression in E. coli Rosetta cells at 37 
°C.  Rosetta cells were chosen because the CnR2 gene contains a total of 30 rare 
codons21.  The extra tRNA in Rosetta cells afforded coverage of 77% of the rare codons 
compared with BL21-RIL cells, which only covered 33%.  LB + antibiotic was 
inoculated with a 1% volume saturated liquid culture and shaken at 200 rpm until OD600 
~ 0.6.  Cells were induced with 0.1-1 mM IPTG and grown for at least 3 hours.  
Uninduced and induced cell aliquots were normalized for OD600 and run side by side on 
SDS-PAGE gels to evaluate the presence (or absence) of an overexpressed protein band 
of the expected size.  Expression in SHuffle cells (NEB) was attempted for the intein-
CBD-tagged constructs, but this was unsuccessful at 30 °C. 
In order to assess solubility, cells were grown in an identical way to expression 
until induction.  After induction, cells were grown at 37 °C (~3 hours), ambient 
temperature (~8 hours) or 16 °C (~20 hours).  Cells were lysed using French Press and 
cell lysate was separated into supernatant and pellet.  Aliquots were run side by side on 
SDS-PAGE gels to compare the proportion of the overexpressed band in the supernatant 
(soluble) and pellet (insoluble).   
Purification 
French press was used as the cell lysis method for all constructs.  For intein-
CBD-tagged constructs (C-D), the lysis buffer was 50 mM sodium phosphate, pH 8.0, 
500 mM NaCl, 0.1 mM EDTA, 0.1% Triton X-100 and 5% glycerol.  For His-tagged 
constructs (E-M), lysis buffer was 20-50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 
1 mM βME and 5 mM imidazole.  Just prior to lysis, DNase, RNase and 1X protease 
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inhibitor were added.  After lysis, cell lysate was clarified for 1 hour at ~25000 x g, 4 
°C. 
The first purification step for intein-CBD-tagged constructs (C-D) was chitin 
affinity chromatography (IMPACT system, NEB).  Cell lysate supernatant from 1-L 
scale up preps was added to a 3-4 mL chitin column pre-equilibrated in lysis buffer.  
The flow through was discarded and the column was washed with 10 CV of lysis buffer 
and 10 CV of cleavage buffer (50 mM sodium phosphate pH 8.0, 100 mM NaCl, 0.1 
mM EDTA and 5% glycerol).  The column was left to incubate overnight in cleavage 
buffer + 30 mM βME at 4 °C.   Cleaved protein was eluted with cleavage buffer and 
collected in 1 mL fractions. 
Nickel or cobalt affinity columns (hand-poured or HP Chelating (GE 
Healthcare)) were performed as the first purification step for all His-tagged proteins 
(constructs E-M).  After clarification, cell lysate was applied to pre-equilibrated 
columns.  When gravity columns were used, a wash step with lysis buffer + 100 mM 
imidazole was used before elution with lysis buffer + 600 mM imidazole.  When 5-mL 
HP chelating columns (GE Healthcare) were used with the AKTA prime system, a 
gradient from 5 mM imidazole to 600 mM imidazole in lysis buffer was used with a 
flow rate of 1 mL/min. 
Size exclusion chromatography was generally attempted as a second purification 
step.  Proteins were concentrated to approximately 1 mL and filtered through 0.45 µm 
filters before being added to a 100-mL column of Sephacryl-100 resin at 4 °C.  Various 
buffer components were used but in general, the buffer was pH 7-8 and included 100-
120 
150 mM salt along with 1 mM EDTA and 1 mM βME.  Other additions were 5-15 mM 
MgCl2 or 5-10% glycerol. 
Occasionally cation exchange was performed as a second purification step.  
Protein was dialyzed into 50 mM HEPES pH 7.6, 5% glycerol and 1 mM βME.  Protein 
was loaded onto a 5 mL HiTrap SP column (GE Healthcare) and washed with buffer.  A 
gradient of 0-1 M NaCl was applied over 90 mL at 1 mL/min flow rate.   
In the case of CnR2-D, a phenyl sepharose column was attempted as a second 
purification step.  Protein (in lysis buffer) was added to a 2-mL pre-equilibrated phenyl 
sepharose column.  The column was washed with lysis buffer and elution fractions were 
collected as salt was decreased step-wise from 500 mM to 0 mM. 
Table 9.  Summary of protein purification. 
construct expression solubility 
affinity 
chromatography 
other 
chromatography 
phosphotransfer 
assay 
B no n/a n/a n/a n/a 
C yes yes chitin 
cation exchange, gel-
filtration 
n/a 
D yes yes chitin 
cation exchange, 
phenyl sepharose, gel-
filtration 
not active with 
CnYpd1 
E yes yes nickel, cobalt 
cation exchange, gel-
filtration 
n/a 
F yes yes nickel n/a n/a 
G yes yes nickel n/a n/a 
H n/a n/a n/a n/a n/a 
I yes no n/a n/a n/a 
J yes yes nickel, cobalt gel-filtration 
not active with 
CnYpd1 
K yes no n/a n/a n/a 
L yes no n/a n/a n/a 
M yes no n/a n/a n/a 
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Appendix A: Co-crystallization of Ssk1-R2W638A and Ypd1G68Q 
Introduction 
All HPt proteins with a known structure have a similar fold; at their core is a 4-
α-helix bundle1-4.  This core 4-helix bundle is structurally similar to the α-helical 
dimerization domain of HKs that contains the phosphorylatable histidine5.  Histidine 
kinase and HPt protein domains show a low amino acid sequence homology, but the 
area surrounding the phospho-accepting histidine is widely conserved.  The importance 
of a small residue at the n+4 position relative to the phosphorylatable histidine in HPt 
domains is evident from a comprehensive sequence alignment (data not shown) of HPt 
domains.  A glycine or serine is conserved in approximately 99% of sequences in the 
NCBI database for the HPt Superfamily6, 7.   
A previous study of the S. cerevisiae Sln1-Ypd1-Ssk1 signaling pathway in vitro 
led to the elucidation of a common binding surface on Ypd1 for the upstream and 
downstream response regulators8, 9.  Mutations of highly conserved residues in Ypd1 
were shown to alter phosphotransfer activity10.  A mutant that contained an n+4 glycine 
substitution with a glutamine residue (G68Q) showed a steady-state level of 
phosphorylation of approximately 30% of wild-type Ypd1 while maintaining a 
phosphorylated half-life comparable to wild-type Ypd1.  In addition, this mutant also 
exhibited reduced phosphotransfer capability to the upstream and downstream response 
regulator receiver domains, Sln1-R1 and Ssk1-R210.  The role of this conserved glycine 
residue in this position has remained an open question.  In order to visualize the impact 
of the glutamine substitution in the n+4 position, I describe methods that led to the 
successful co-crystallization of Ssk1-R2-W638A with Ypd1-G68Q. 
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Co-crystallization of Ssk1-R2W638A and Ypd1G68Q 
Diffraction-quality crystals were produced in 1:1 µL hanging drops in a 24-well 
hanging drop screens around conditions similar to Ssk1-R2-W638A and Ypd1 as 
described in Chapter 3.  In addition, crystals were grown under similar conditions in an 
attempt to get the BeF3
- -activated structure (Figure 70).  Optimal cryo conditions must 
be found to obtain high resolution data to solve the crystal structures.   
 
Figure 70.  Ssk1-R2W638A/Ypd1G68Q crystal.   
Photograph of Ssk1-R2W638A/Ypd1G68Q crystal (left panel) and Coomassie-stained 15% SDS-PAGE gel of 
a dissolved crystal, verifying that the crystals were composed of both proteins (right panel).  Coomassie 
gel courtesy of Clay Foster. 
 
Experimental Section 
Protein Purification 
Ypd1-G68Q was purified using an identical protocol to WT Ypd1 by 
ammonium sulfate precipitation, ion exchange chromatography and size-exclusion 
chromatography as published in Xu et al.11 and described in Chapter 3.     
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Ssk1-R2-W638A was purified using the IMPACT (NEB) system as described in 
Chapter 2.  It was followed by size-exclusion chromatography (Sephadex® G-75, 
Sephacryl® S-100 or S-200) in 20 mM Tris pH 8, 100 mM NaCl and 1% glycerol.   
Crystallization and data collection 
To produce apo-crystals, equimolar amounts of Ssk1-R2-W638A and Ypd1-
G68Q were combined, co-concentrated to 12 mg/mL in 20 mM Tris pH 8.0, 75-100 
mM NaCl and 1% glycerol.  Hanging drop vapor diffusion 24-well trays were set up 
with well solutions of 0.1M CAPS pH 10.5, 1.15-1.2 M NaH2PO4, 0.7-0.8 M K2HPO4 
and 0.2 M LiSO4.  To attempt to produce BeF
3--activated crystals, equimolar amounts 
of Ssk1-R2-W638A and Ypd1-G68Q were combined, co-concentrated to 11.7 mg/mL 
in 20 mM Tris pH 8.0, 75-100 mM NaCl and 1% glycerol, 15 mM MgCl2, 5 mM BeCl2 
and 35 mM NaF. Hanging drop vapor diffusion 24-well trays were set up in an identical 
way to the apo crystals.  Attempts to optimize cryo conditions were unsuccessful, but 
the most promising results were obtained using 30% or saturated sucrose in mother 
liquor compared to varying amounts of high salt, glycerol, ethylene glycol, PEG 3350, 
lithium sulfate, glucose, trehalose, CryoProtX (Molecular Dimensions), Krytox oil, or 
Al’s oil.  A room temperature mount collected on our home X-ray source (1.541 Å Cu 
Kα rotating anode with Pilatus 200K detector (Rigaku)) showed that the crystals 
diffracted from 3.5-4.0 Å (Figure 71 (pg. 126)). 
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Figure 71.  Diffraction to ~3-4 Å of the co-crystal of Ssk1-R2W638A/Ypd1G68Q. 
 
Future Directions 
The next steps that need to be taken in this project are to optimize cryo 
conditions, obtain data to a minimum of 3.0 Å and solve the crystal structure using 
molecular replacement.  The information will elucidate the structural basis for the loss 
in phosphotransfer efficiency observed between Ypd1 and its cognate response 
regulators that cannot be explained by preliminary binding data.  This project has been 
conducted in collaboration with, and will be completed by Clay Foster, West Lab.  
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Appendix B: Table of West Lab primers, plasmids and cell strains 
organism protein oligos 
restriction 
sites 
plasmid 
storage 
strain 
expression 
strain(s) 
Cn 
Ssk1-5' 
cDNA (2a) 
n/a n/a 
pCR2.1 
TOPO 
OU689-
DH5α 
n/a 
Cn Ssk1-5' 
cDNA (2b) 
n/a n/a 
pCR2.1 
TOPO 
OU690-
DH5α 
n/a 
Cn Ssk1-5' 
cDNA (5a) 
AW902 
for mid-
DNA seq 
pCR2.1 
TOPO 
n/a n/a 
Cn Ssk1-3' 
cDNA (6a) 
n/a n/a 
pCR2.1 
TOPO 
OU691-
DH5α 
n/a 
Cn Ssk1-3' 
cDNA (6b) 
n/a n/a 
pCR2.1 
TOPO 
OU692-
DH5α 
n/a 
Cn 
Ssk1-R2-B 
AW727, 
AW728 
n/a pl424 
OU647-
DH5α 
OU645-
Rosetta 
Cn 
Ssk1-R2-C 
AW729, 
AW730 
NdeI, SmaI pl425 
OU656-
DH5α 
OU654-
Rosetta 
Cn 
Ssk1-R2-D 
AW729, 
AW731 
NdeI, SmaI pl428 
OU661-
DH5α 
OU662-
Rosetta 
Cn 
Ssk1-R2-E 
AW729, 
AW783 
NdeI, 
BamHI 
pl436 
OU686-
DH5α 
OU687-
Rosetta 
Cn Ssk1-R2-E-
W1147A 
AW869, 
AW870 
NdeI, 
BamHI 
pl449 
OU721-
DH5α 
OU722-
Rosetta 
Cn Ssk1-R2-F-
TOPO 
AW903, 
AW904 
NdeI, XhoI pl462 
OU751-
DH5α 
n/a 
Cn Ssk1-R2-J-
TOPO 
AW903, 
AW908 
NdeI, XhoI pl463 
OU752-
DH5α 
n/a 
Cn Ssk1-R2-K-
TOPO 
AW903, 
AW909 
NdeI, XhoI pl464 
OU753-
DH5α 
n/a 
Cn Ssk1-R2-L-
TOPO 
AW905, 
AW908 
NdeI, XhoI pl465 
OU754-
TOP10 
n/a 
Cn Ssk1-R2-G-
TOPO 
AW905, 
AW904 
NdeI, XhoI pl466 
OU755-
TOP10 
n/a 
Cn 
Ssk1-R2-F 
AW903, 
AW904 
NdeI, XhoI pl467 
OU756-
DH5α 
OU757-
Rosetta 
Cn 
Ssk1-R2-J 
AW903, 
AW908 
NdeI, XhoI pl468 
OU758-
DH5α 
OU759-
Rosetta 
Cn 
Ssk1-R2-K 
AW903, 
AW909 
NdeI, XhoI pl469 
OU760-
TOP10 
OU761-
Rosetta 
Cn 
Ssk1-R2-L 
AW905, 
AW908 
NdeI, XhoI pl470 
OU762-
TOP10 
OU763-
Rosetta 
Cn 
Ssk1-R2-G 
AW905, 
AW904 
NdeI, XhoI pl471 
OU764-
TOP10 
OU765-
Rosetta 
Cn Ssk1-R2-I-
TOPO 
AW905, 
AW907 
NdeI, XhoI pl472 
OU766-
TOP10 
n/a 
Cn Ssk1-R2-M-
TOPO 
AW905, 
AW909 
NdeI, XhoI pl473 
OU767-
TOP10 
n/a 
Cn 
Ssk1-R2-I 
AW905, 
AW907 
NdeI, XhoI pl474 
OU768-
DH5α 
OU769-
Rosetta 
Cn 
Ssk1-R2-M 
AW905, 
AW909 
NdeI, XhoI pl475 
OU770-
DH5α 
OU771-
Rosetta 
Cn Ssk1-R2-H-
TOPO 
AW905, 
AW906 
NdeI, XhoI pl520 n/a n/a 
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Cn 
Ssk1-R2-H 
AW905, 
AW906 
NdeI, XhoI n/a n/a n/a 
Sc 
Ssk1-R2-
D554N 
AW741, 
AW742 
NdeI, SmaI pl429 
OU663-
DH5α 
OU735-
BL21 Star, 
OU664-
BL21 Gold 
Sc Ssk1-R2-
W638A 
AW776, 
AW777 
NdeI, SmaI pl430 
OU668-
DH5α 
OU738-
BL21 Star, 
OU669-
BL21 Gold 
Sc Ssk1-R2-
Q650L 
AW745, 
AW746 
NdeI, SmaI pl431 
OU670-
DH5α 
OU737-
BL21 Star, 
OU671-
BL21 Gold 
Sc Ssk1-R2-
G647Q 
AW743, 
AW744 
NdeI, SmaI pl439 
OU695-
DH5α 
OU736-
BL21 Star, 
OU696-
BL21 Gold 
Sc Ssk1-R2-
V634S 
AW786, 
AW787 
NdeI, SmaI pl445 
OU709-
DH5α 
OU710-
BL21 Star 
Sc Ssk1-R2-
I518S 
AW784, 
AW785 
NdeI, SmaI pl446 
OU711-
DH5α 
OU712-
BL21 Star 
Sc Ssk1-R2-
W646A 
AW860, 
AW861 
NdeI, SmaI pl447 
OU713-
DH5α 
OU714-
BL21 Star 
Sc Ssk1-R2-
E645Q 
AW778, 
AW779 
NdeI, SmaI pl448 
OU715-
DH5α 
OU716-
BL21 Star 
Sc Ssk1-R2-
D554A 
AW856, 
AW857 
NdeI, SmaI pl455 
OU733-
DH5α 
OU734-
BL21 Star 
Sc Ssk1-R2-
L639S 
AW858, 
AW859 
NdeI, SmaI pl457 
OU741-
DH5α 
OU742-
BL21 Star 
Sc Ssk1-R2-
S612A 
AW921, 
AW922 
NdeI, SmaI pl458 
OU743-
DH5α 
OU744-
BL21 Star 
Sc Ssk1-R2-
T631A 
AW923, 
AW924 
NdeI, SmaI pl459 
OU745-
DH5α 
OU746-
BL21 Star 
Sc Ssk1-R2-
L636S 
AW925, 
AW926 
NdeI, SmaI pl460 
OU747-
DH5α 
OU748-
BL21 Star 
Sc Ssk1-R2-
N635A 
AW854, 
AW855 
NdeI, SmaI pl461 
OU749-
DH5α 
OU750-
BL21 Star 
Sc Ssk1-R2-
Q556A 
AW1012, 
AW1013 
NdeI, SmaI pl483 
OU781-
DH5α 
OU782-
BL21 Star 
Sc Ssk1-R2-
R524A 
AW1014, 
AW1015 
NdeI, SmaI pl484 
OU783-
DH5α 
OU784-
BL21 Star 
Sc Ssk1-R2-
H637A 
AW984, 
AW985 
NdeI, SmaI pl485 
OU785-
DH5α 
OU786-
BL21 Star 
Sc 
Ssk1-R2-
R524A-
H637A 
AW1014, 
AW1015, 
AW984, 
AW985 
NdeI, SmaI pl486 
OU787-
DH5α 
OU788-
BL21 Star 
Sc Ssk1-R2-
K525A 
AW1035, 
AW1036 
NdeI, SmaI pl493 
OU798-
DH5α 
OU799-
BL21 Star 
Sc 
Ssk1-R2-
R524A-
K525A 
AW1014, 
AW1015, 
AW1035, 
AW1036 
NdeI, SmaI pl494 
OU800-
DH5α 
OU801-
BL21 Star 
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Sc 
Ssk1-R2-
R524A-
K525A-
H637A 
AW1014, 
AW1015, 
AW984, 
AW985, 
AW1035, 
AW1036 
NdeI, SmaI pl495 
OU804-
DH5α 
OU805-
BL21 Star 
Sc 
Ssk1-R2-
K525A-
H637A 
AW1035, 
AW1036, 
AW984, 
AW985  
NdeI, SmaI pl496 
OU802-
DH5α 
OU803-
BL21 Star 
Cn= C. neoformans, Sc= S. cerevisiae 
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Appendix C: Discovery of anti-biofilm isocoumarins and 
isobenzofuranones from a microbial mat fungus 
 
List of Abbreviations 
NMR: Nuclear Magnetic Resonance 
HRESIMS: High Resolution ElectroSpray Ionization Mass Spectrometry 
DBE: Double Bond Equivalents 
gCOSY: gradient COrrelation SpectroscopY: a two dimensional NMR experiment 
showing cross-peaks between neighboring protons 
NOESY: Nuclear Overhauser Effect SpectroscopY: an NMR experiment showing 
correlations between protons within 6 Å from each other in space 
HSQC: Heteronuclear Single Quantum Coherence/Correlation: a two-dimensional 
NMR experiment showing cross-peaks between protons and carbons connected by one 
bond 
gHMBC: gradient Heteronuclear Multiple Bond Correlation: a two-dimensional NMR 
experiment showing cross-peaks between protons and carbons separated by two to three 
bonds 
Introduction 
Isocoumarins are a broad class of secondary metabolites produced by bacteria, 
plants and fungi.  These metabolites and their derivatives have traditionally exhibited an 
extensive variety of bioactivities ranging from antimicrobial effects to anti-
inflammatory to anti-angiogenic properties1.  Isobenzofuranone natural products have 
also been shown to have useful bioactive properties2.  An area currently in need of new 
bioactive lead compounds is the treatment of systemic fungal infections.  Only a limited 
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selection of therapies exist for combating pathogenic fungal infections, often with 
severe side effects (host toxicity) and low efficacy (emerging drug resistance)3.  Over 
one million people with compromised immune systems die each year from systemic 
fungal infections4.  One of the most common human pathogens, Candida albicans, is 
responsible for a large percentage of these deaths.  C. albicans is able to maintain a 
relatively benign yeast form under normal conditions, but becomes pathogenic by 
forming a biofilm within an infected host.  Traditional antifungal therapies focus on the 
elimination of the pathogen itself, but counteracting this biofilm formation is another 
viable method for treating C. albicans infections.   
The aim of this study was to evaluate a previously undiscovered 
Dothideomycete species from an iron-rich microbial mat community and search for 
antimicrobial secondary metabolites.  During the investigation of this fungus, five 
structurally related secondary metabolites were found (Figure 72 (pg. 134))5.  Three 
isobenzofuranones (compound 1, compound 2a, compound 2b) and two isocoumarins 
(compound 3, compound 4) were isolated and structurally elucidated.  Compound 1 
(C13H16O5 by HRESIMS) and compound 4 (C13H14O5 by HRESIMS) have been 
previously reported in the literature6, 7.  Comparison of NMR, optical rotation and 
circular dichroism (CD) data confirmed that the compounds were compound 1and 
compound 4.   This is the first report of the discovery of natural products 2a, 2b and 3. 
Compound 3 was named clearanol C while compounds 2a and 2b were named clearanol 
D and E, respectively.  After evaluation of antimicrobial and anti-biofilm properties, the 
isocoumarins were found to prevent C. albicans biofilm growth through inhibition of 
hyphae formation5. 
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Figure 72.  Structures of compounds 1-4.  
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Structural elucidation of clearanol C 
Table 10.  Summary of NMR data for clearanol C. 
clearanol C 
position δC type δH (J in Hz) HMBC 
1 166.6 C    
2 99.5 C    
3 164.5 C    
4 98.5 CH 6.46 s 2,3,5,6 
5 168.5 C    
6 115.5 C    
7 143.8 C    
8 36.0 CH 3.99 q (7.0) 2,6,7,11 
9 159.1 C    
10 96.2 CH2 4.74, 4.68 s,s 8,9 
11 22.7 CH3 1.34 d (7.0) 7,8,9 
12 10.2 CH3 2.09 s 5,6,7 
13 56.6 CH3 3.88 s 5 
 
Compound 3 (clearanol C) (C13H14O4 by HRESIMS, DBE = 7) is a newly 
discovered isocoumarin with strong similarity to the known compound 4.  The only 
difference between the planar structures is the absence of a hydroxyl group attached to 
C-8 (δ 36.0) in compound 3 that is present in compound 4 (C-8, δ 72.6).  Evidence for 
this conclusion includes the absence of one oxygen atom in the chemical composition of 
3 compared to 4.  Furthermore, all carbon chemical shift values are virtually identical 
between compounds 3 and 4 (average Δδ = 1.1), except C-8 and the methyl group 
attached to C-8 (C-11, compound 3: δ 22.7, compound 4: δ 29.6.)  In addition, position 
C-8 in 3 is protonated (H-8, δH 3.99, J = 7.0) and split into a quartet by the methyl 
protons of C-11, which appear as a doublet (H-11, δH 1.34, J = 7.0).  Complete data sets 
of 1D and 2D NMR spectra (1H, 13C, gCOSY, HSQC, gHMBC) were collected for 
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compound 3 to confirm the structure (Table 10 (pg. 135), Figure 73 - Figure 77 (pg. 
137-141)).  Carbon chemical shifts of C-2 (δ 99.5), C-3 (δ 164.4), C-4 (δ 98.5), C-5 (δ 
168.4), C-6 (δ 115.5) and C-7 (δ 143.8) were consistent with a penta-substituted phenyl 
ring.  Substituents to the ring were assigned based on chemical shifts, HSQC and 
gHMBC correlations.  Firstly, a methyl group was assigned to position C-6 based on a 
chemical shift value of 115.5, typical for a methyl substitution, and HMBC correlations 
from the methyl protons (H-12, δH 2.09) to C-5, C-6, and C-7.  A methoxy group was 
assigned to position C-5 (δ 168.4) based on an HMBC correlation from H-13 (δH 3.88) 
to C-5 and the chemical shift value of C-5, which is consistent with an oxygen 
substitution.  The sole proton on the ring (H-4, δH 6.46) showed HMBC correlations to 
C-2, C-3, C-5, and C-6, and so was placed para to C-7.  A hydroxyl group was assigned 
to position C-3 (δ 164.4) based on a chemical shift value consistent with oxygen 
connectivity.  The quaternary carbon C-7 (δ 143.8) was placed next to C-8 based on an 
HMBC correlation from H-11 to C-7, C-8, and C-9, which consequently placed C-9 on 
the other side of C-8.  The double bond between C-10 (δ 96.2) and C-9 (δ 159.1) was 
confirmed by chemical shift values consistent with a terminal methylene group and the 
HMBC correlations from H-10 (δH 4.68, δH 4.74) to C-8 and C-9.  The lack of an 
HMBC correlation from H-10 to a third carbon and the high chemical shift of C-9 (δ 
159.1) indicated that C-9 was located between C-8 and an oxygen atom.  The chemical 
shift of C-1 (δ 166.6) was consistent with an ester functionality, which indicated the 
presence of a carbonyl on the opposite side of the oxygen atom; a fusion of this carbon 
to the quaternary carbon C-2 satisfied the double bond equivalent requirements 
calculated from the chemical formula.   
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Compound 3 contains one stereocenter at the C-8 position.  To determine 
absolute configuration, optical rotation and CD data were collected and compared to a 
similar isocoumarin with an identical stereocenter: (S)-(+)-ascochin8.  Compound 3 
showed a positive optical rotation, a negative Cotton effect at 210 nm and a positive 
Cotton effect at 233 nm, consistent with the experimental CD spectra of (S)-ascochin.  
Therefore, the absolute configuration of the C-8 stereocenter was determined to be S.   
 
Figure 73.  1H NMR spectrum (400 MHz, methanol-d4) of clearanol C. 
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Figure 74.  13C NMR spectrum (100 MHz, methanol-d4) of clearanol C. 
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Figure 75.  gCOSY NMR spectrum (400 MHz, methanol-d4) of clearanol C. 
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Figure 76.  HSQC NMR spectrum (400, 100 MHz, methanol-d4) of clearanol C. 
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Figure 77.  gHMBC NMR spectrum (400, 100 MHz, methanol-d4) of clearanol C. 
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Structural elucidation of clearanols D and E 
Table 11.  Summary of NMR data for clearanols D and E. 
clearanols D and E 
position δC type δH (J in Hz) δC type δH (J in Hz) HMBC 
1 171.9 C   171.5 C    
2 105.4 C   104.6 C    
3 157.8 C   158.3 C    
4 99.5 CH 6.47 s 99.9 CH 6.49 s 1,2,3,5,
6,12 
5 166.4 C   166.6 C    
6 113.4 C   113.3 C    
7 153.1 C   152.4 C    
8 90.6 C   90.4 C    
9 75.7 CH 4.13 dd (8.0, 3.7) 76.2 CH 4.11 dd (8.2, 2.7) 10 
10 63.9 CH2 3.83, 
3.53 
dd (11.3, 3.5), 
dd (11.3, 8.2) 
63.3 CH2 3.34, 
3.14 
dd (11.3, 8.6), 
dd (11.3, 2.7) 
8,9 
11 22.08 CH3 1.67 s 22.11 CH3 1.73 s 7,8,9 
12 11.4 CH3 2.18 s 11.7 CH3 2.15 s 5,6,7 
13 56.9 CH3 3.87 s 56.9 CH3 3.88 s 5 
 
Compound 2 (clearanols D and E) (C13H16O6 by HRESIMS, DBE = 6) is a 
diastereomeric mixture of new isobenzofuranones that are structurally related to the 
known compound 1.  The major difference between the planar structures is the addition 
of a hydroxyl group at the C-10 position in compound 2.  In 1, C-10 (δ 17.4) is a methyl 
group, while in 2a (C-10, δ 63.9) and 2b (C-10, δ 63.3), it is a methylene with a 
terminal hydroxyl group.  All other carbon chemical shift values are identical between 
compound 1 and compound 2 (average Δδ = 0.7).  Data sets of 1D and 2D NMR were 
collected on 1 and 2 (Table 11, Figure 78 - Figure 82 (pg. 144-148)) for full structure 
elucidation.  In addition, variable temperature 1H and 1D NOESY experiments were 
performed on the compound 2 mixture to determine the separate chemical identities of 
2a and 2b.   
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Because the compound 2 mixture was inseparable by semi-preparative HPLC, 
the 1H and 13C NMR data were “doubled” (Figure 78 - Figure 79 (pg. 44-45)).  These 
data could be interpreted in two ways: compound 2 contained one molecule in a 
tautomeric “flux” at room temperature, or it contained two different diastereomeric 
molecules.  In order to determine which explanation was correct, variable temperature 
1H experiments were performed (4 °C, 20 °C, 50 °C), with the rationale that increasing 
temperatures would rapidly interconvert any tautomeric forms of the same molecule and 
the doubled peaks would merge.  Instead, a marked separation of 1H peaks between 3.0 
and 4.0 ppm was observed at 50 °C (Figure 83 (pg. 149)).  This evidence indicated that 
compound 2 was actually a mixture of diastereomers. The 1H and 13C chemical shifts 
were distinct enough to be accurately separated into two discrete molecules with 
identical planar structures: clearanol D (2a) and clearanol E (2b). 
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Figure 78. 1H NMR spectrum (400 MHz, methanol-d4) of clearanol D/E. 
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Figure 79.  13C NMR spectrum (100 MHz, methanol-d4) of clearanol D/E. 
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Figure 80.  gCOSY NMR spectrum (400 MHz, methanol-d4) of clearanol D/E. 
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Figure 81.  HSQC NMR spectrum (400, 100 MHz, methanol-d4) of clearanol D/E. 
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Figure 82.  gHMBC NMR spectrum (400, 100 MHz, methanol-d4) clearanol D/E. 
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Figure 83.  1H NMR variable temperature experiments for clearanol D/E. 
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After structural elucidation, Compounds 1-4 were subjected to antibacterial, 
antifungal and anti-biofilm formation assays.  Compounds 1, 2 and 4 exhibited no 
antibiotic properties.  However, compound 3 showed mild antifungal effects when 
tested against Candida albicans (ATCC 38245) and Aspergillus fumigatus (FGSC 
A1100) at 100 μg/mL by reducing growth 61% and 62%, respectively5.  The effects of 
compounds 1-4 on C. albicans growth and biofilm formation were evaluated in 96-well 
polystyrene microplates. C. albicans DAY185 cells were treated with various 
concentrations (6.25–200 µM) of test compounds or DMSO as negative control at 37 ºC 
for 48 h.  Compound 3 and Compound 4 showed moderate biofilm inhibition activity 
with MIC values of 101 ±3 and 86 ± 3 μM, respectively5. 
Experimental Section 
General Experimental Procedures 
Optical rotation measurements were taken on a Rudolph Research Analytical 
Autopol® III polarimeter at 22 °C (solvent: methanol, cell length: 0.5 dm).  CD 
measurements were taken on an AVIV Instruments, Inc. Circular Dichroism 
Spectrometer, model 202-01 (solvent: methanol with trace amounts of acetonitrile).   IR 
spectra were collected in solution (methanol) between two NaCl plates on a Bio-Rad 
FT-155 FTIR spectrometer.  NMR data were obtained on Varian VNMR spectrometers 
(300, 400 and 500 MHz for 1H and 75, 100 and 125 MHz for 13C) with 4-nuclei 
autoswitchable PFG, broad band and triple resonance probes at 20-25 °C.  NMR spectra 
were processed with ACD Labs software. HRESIMS data were obtained by 
electrospray ionization employing an Agilent 6538 UHD Accurate-Mass Quadrupole 
TOF mass analyzer.  LCMS data were collected on a Finnigan LCQ-Deca equipped 
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with a Surveyor PDA Plus Detector, autosampler and MS pump.  LC conditions 
consisted of methanol-water (0.1% formic acid) gradients on a 3μm Luna C18 column.  
HPLC separations were performed on preparative and semi-preparative Shimadzu 
systems equipped with 5μm Gemini or Luna C18 columns (250 x 21.20 mm at 10 
mL/min flow rate for preparative HPLC and 250 x 10.00 mm at 2 mL/min flow rate for 
semi-preparative HPLC.)   
Fungal Materials 
Fungal samples were collected from a microbial mat formed near the 
intersection of a spring (39° 45’ 15.0” North, 105° 13’ 39.9” West) and Clear Creek 
River in north central Colorado.  Sequencing of the internal transcribed spacer (ITS) 
region (Scheme 1) of the organism revealed 98% identity to Uncultured 
Dothideomycete isolate s_C03_05.ab1.  Scale-up fungal cultures were grown statically 
on ~24 g of Cheerios® cereal in 1L flasks for one month.  Twenty-two flasks were 
prepared by adding ~200 mL (~24 g) of cereal and autoclaving.  Then, 120 mL of 
sterile 3 g/L sucrose water was added along with a slice of fungal material from an agar 
plate.   
Scheme 1.  ITS sequence of undescribed Dothideomycete. 
NGGCATCCTCCNGATCCGAGGGTCAAAGTGTTAAATAGACTTGGATGGTTG
CAAGCTAATTATTAGCTAGAGTCGCAAATTGTGCTGCGCTTCTATACCAATA
CACTGGCTGCCAATTTCTTTAAGGCGAGTCCAAACGCAAGGGAGAGGACAA
ACACCCAACACCAAGCATAGCTTGAGGGTACAAATGACGCTCGAACAGGCA
TGCCCCATGGAATACCAAGGGGCGCAATGTGCGTTCAAAGATTCGATGATT
CACTGAATTCTGCAATTCACACTACTTATCGCATTTCGCTGCGTTCTTCATCG
ATGCCAGAACCAAGAGATCCGTTGTTGAAAGTTGTAATTATTATAGTTATTC
AGACGCTGATTGAAAATTAAAAAGGTTTTAGAATTGTCCATTCGGCAGGCA
AGCCCACCGAGGAAACATGAGTACGCAAAAGACAAGGGTGCAGACAGGGG
GCTTACTCGTGATCCAGTAATCAAACTGGGACTTTCCACCCCCCCGATCAGT
AGAAATCTACTGTATTTAATGATCCTTCCGCAGGTTCCCCNTACGGAAGANN
NNNNNNN 
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Extraction and Isolation 
Fungal cultures were extracted using 250 mL ethyl acetate per flask three times 
at room temperature.  Crude extract (2.8 g) was subjected to gel-filtration 
chromatography (Sephadex® LH-20) in 1:1 MeOH:DCM, which afforded 10 fractions.  
Fractions 6 and 7 were combined and subjected to preparative HPLC (water, 40-100% 
MeOH gradient).  These fractions were further purified using semi-preparative HPLC to 
yield compound 1 (water, 43% MeCN; 19.5 mg), compounds 2a and 2b (water, 32% 
MeCN; 39.2 mg), compound 3 (water, 63% MeCN; 3.1 mg), and compound 4 (water, 
55% MeCN; 5.0 mg). 
Compound 1: amorphous solid; [α]22D -33 (c 1.3, MeOH); UV (MeOH) max (log ) 
218 (4.40), 260 (4.04), 300 (3.75) nm; 1H NMR (400 MHz, METHANOL-d4) δ = 6.48 
(1H, s, H-4), 4.22 (1H, q, J = 6.3 Hz, H-9), 3.87 (3H, s, H-13), 2.12 (3H, s, H-12), 1.73 
(3H, s, H-11), 0.86 (3H, d, J = 6.3 Hz, H-10); 13C NMR (101 MHz, METHANOL-d4) δ 
= 172.1 (C, C-1), 166.6 (C, C-5), 158.5 (C, C-3), 153.0 (C, C-7), 112.8 (C, C-6), 105.0 
(C, C-2), 99.9 (CH, C-4), 91.6 (C, C-8), 71.3 (CH, C-9), 56.9 (CH3, C-13), 21.7 (CH3, 
C-11), 17.4 (CH3, C-10), 11.6 (CH3, C-12); HRESIMS m/z 275.0896 [M+Na]
+, (calcd 
for C13H16O5Na, 275.0896). 
Compound 2a (clearanol D): amorphous solid (1:1 mixture with clearanol E); [α]22D -
15 (c 2.1, MeOH); UV (MeOH) max (log ) 218 (4.22), 260 (3.87), 300 (3.59) nm; IR 
(NaCl) vmax 3596, 3089, 1737, 1651, 1472, 1373, 1319, 1247, 1220, 1153, 1067 cm
-1; 
1H NMR (400 MHz, METHANOL-d4) δ = 6.47 (1H, s, H-4), 4.13 (1H, dd, J = 8.0 Hz, J 
= 3.7 Hz, H-9), 3.87 (3H, s, H-13), 3.83 (1H, dd, J = 11.3 Hz, J = 3.5 Hz, H-10a), 3.53 
(1H, dd, J = 11.3 Hz, J = 8.2 Hz, H-10b), 2.18 (3H, s, H-12), 1.67 (3H, s, H-11); 13C 
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NMR (101 MHz, METHANOL-d4) δ = 171.9 (C, C-1), 166.4 (C, C-5), 157.8 (C, C-3), 
153.1 (C, C-7), 113.4 (C, C-6), 105.4 (C, C-2), 99.5 (CH, C-4), 90.6 (C, C-8), 75.7 (CH, 
C-9), 63.9 (CH2, C-10), 56.9 (CH3, C-13), 22.08 (CH3, C-11), 11.4 (CH3, C-12); 
HRESIMS m/z 291.0839 [M+Na]+, (calcd for C13H16O6Na, 291.0845). 
Compound 2b (clearanol E): amorphous solid (1:1 mixture with clearanol D); [α]22D -
15 (c 2.1, MeOH); UV (MeOH) max (log ) 218 (4.22), 260 (3.87), 300 (3.59) nm; IR 
(NaCl) vmax 3596, 3089, 1737, 1651, 1472, 1373, 1319, 1247, 1220, 1153, 1067 cm
-1; 1H 
NMR (400 MHz, METHANOL-d4) δ = 6.49 (1H, s, H-4), 4.11 (1H, dd, J  = 8.2 Hz, J = 
2.7 Hz, H-9), 3.88 (3H, s, H-13), 3.34 (1H, dd, J = 11.3 Hz, J = 8.6 Hz, H-10a), 3.14 
(1H, dd, J = 11.3 Hz, J = 2.7 Hz, H-10b), 2.15 (3H, s, H-12), 1.73 (3H, s, H-11); 13C 
NMR (101 MHz, METHANOL-d4) δ = 171.5 (C, C-1), 166.6 (C, C-5), 158.3 (C, C-3), 
152.4 (C, C-7), 113.3 (C, C-6), 104.6 (C, C-2), 99.9 (CH, C-4), 90.4 (C, C-8), 76.2 (CH, 
C-9), 63.3 (CH2, C-10), 56.9 (CH3, C-13), 22.11 (CH3, C-11), 11.7 (CH3, C-12); 
HRESIMS m/z 291.0839 [M+Na]+, (calcd for C13H16O6Na, 291.0845). 
Compound 3 (clearanol C): amorphous solid; [α]22D +39 (c 0.06, MeOH); UV 
(MeOH) max (log ) 220 (3.83) 270 (3.47), 312 (3.20) nm; IR (NaCl) vmax 3623, 2949, 
2581, 1651, 1018 cm-1; 1H NMR (400 MHz, METHANOL-d4) δ = 6.46 (1H, s, H-4), 
4.74 (1H, s, H-10a), 4.68 (1H, s, H-10b), 3.99 (1H, q, J = 7.0 Hz, H-8), 3.88 (3H, s, H-
13), 2.09 (3H, s, H-12), 1.34 (3H, d, J = 7.0 Hz, H-11); 13C NMR (101 MHz, 
METHANOL-d4) δ = 168.4 (C, C-5), 166.6 (C, C-1), 164.4 (C, C-3), 159.1 (C, C-9), 
143.8 (C, C-7), 115.5 (C, C-6), 99.5 (C, C-2), 98.5 (CH, C-4), 96.2 (CH2, C-10), 56.6 
(CH3, C-13), 36.0 (CH, C-8), 22.7 (CH3, C-11), 10.2 (CH3, C-12); HRESIMS m/z 
233.0815 [M-H]-, (calcd for C13H13O4, 233.0814). 
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Compound 4: amorphous solid; UV (MeOH) max (log ) 220 (4.15) 270 (3.83), 314 
(3.64) nm; 1H NMR (300 MHz, METHANOL-d4) δ = 6.51 (1H, s, H-4), 5.07 (1H, s, H-
10a), 4.87 (1H, s, H-10b), 3.88 (3H, s, H-13), 2.38 (3H, s, H-12), 1.64 (3H, s, H-11); 
13C NMR (75 MHz, METHANOL-d4) δ = 168.2 (C, C-5), 167.4(C, C-1), 164.6 (C, C-
3), 163.0 (C, C-9), 144.9 (C, C-7), 117.9 (C, C-6), 99.2 (C, C-2), 99.2 (CH, C-4), 95.6 
(CH2, C-10), 56.7 (CH3, C-13), 72.6 (C, C-8), 29.6 (CH3, C-11), 12.4 (CH3, C-12); 
HRESIMS m/z 249.0766 [M-H]-, (calcd for C13H13O5, 249.0763). 
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